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SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS: IN SUPPORT OF 
TRANSLATIONAL THERAPY 
 By David Daniel Rushworth, BS 
Advisory Professor: Laurence Cooper, M.D., Ph. D. 
T cells are blood cells which organize the immune system of the host. These cells are 
necessary for the host to respond appropriately to threats from foreign organisms and 
cancerous growth. However, in the case of certain infections and cancer, T cells are unable to 
respond appropriately to a threat and establish immunity. This leads to disease when the 
infection or cancer is not sufficiently eliminated. On the other hand, T cells can lack tolerance 
for healthy tissue and perceive healthy tissue as infected. The ensuing over-reactive immune 
response also leads to disease. A delicate balance must exist between immunity and tolerance 
to prevent these diseases. Small molecules have been developed to ameliorate human 
diseases resulting from the failure of T cell immunity or T cell tolerance, but these small 
molecules rarely lead to cure. This has driven investigators to develop approaches where T 
cells are modified to target disease in order to restore the balance between immunity and 
tolerance. The results have been promising and include long-term cure of disease. 
Furthermore, genetic modification of T cells has the potential to provide supra-physiological 
capacities to T cells, including targeting infection or cancer in ways that T cells could never 
achieve naturally within the host. These gene therapy approaches are hindered by technical 
challenges such as selecting for genetically-modified T cells and against unwanted T cell 
phenotypes. Here we describe novel methods utilizing unique transgenes and small molecules 
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aimed at improving the selection of genetically-modified T cells for the treatment of disease in 
humans.  
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Chapter 1: INTRODUCTION 
The immunobiology of T cells  
Vertebrate animals have evolved a dedicated system capable of removing foreign 
organisms from within the animal. This organ is called the immune system. The immune 
system is vital to the survival of an animal, and genetic deficiencies within the immune system 
typically lead to disease and death at a young age.  The immune system operates in a 
characteristic way: Large molecules typically found on bacteria, fungi, or viruses, are 
recognized by receptors on innate immune cells in the animal. Innate cells and proteins do not 
change over the life of the animal. These innate cells are activated by a foreign threat to 
secrete proteins called cytokines and chemokines which mobilize the innate and adaptive 
immune system. Adaptive immune cells develop an immune response tailored to remove the 
foreign threat. Both adaptive and innate immune cells are typically found circulating in the blood 
or resting in immune organs, but when cytokines or chemokines are recognized, these immune 
cells travel through the body to the site where the hormones are being secreted.  
The early innate immune response involves proteins such as complement and pattern 
recognition receptors, as well as immune cells, such as macrophages and neutrophils, which 
traffic to these sites.[1] For example, Staphylococcus epidermidus is relatively benign and found 
on the skin while Staphylococcus aureus frequently causes infections and disease,[2] but each 
activate the innate immune system similarly. One of the first immune cells to arrive in an innate 
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immune response is a macrophage. Macrophages engulf foreign organism and cell debris, but 
also carry out a crucial role in further activating the immune system.  
Macrophages and similar cells called dendritic cells engulf foreign matter associated with 
the pathological organism and degrade the foreign matter into smaller components, called 
antigens. Macrophages and dendritic cells then present the foreign matter antigens on their 
surface bound to a family of proteins known as the major histocompatibility complex or MHC. 
The advantage of MHC is that antigens on MHC are recognized by a specialized type of 
immune cell known as a T cell. T cells and B cells constitute the portion of the immune system 
able to adapt to variations in pathological organisms which the innate immune system cannot. 
T cells and B cells therefore constitute the adaptive immune system. Cells like macrophages 
and dendritic cells that present this antigen are called antigen presenting cells (APCs).[3] 
When T cells recognize antigen: MHC complex on APC, then the T cell become activated 
and releases cytokines that activate other immune cells to begin an immune response. The T 
cells also begin to replicate and produce more T cells with the same capacity to respond to the 
same antigen.[1] Cytotoxic T cell (Tcyt), also known as CD8+ T cells, have the capacity to kill 
cells that are expressing target antigen on class I MHC, and this is crucial for the removal of 
intracellular pathological organisms such as bacteria and viruses.[4] When B cells are activated 
or receive cytokine signal from activated T cells, then B cells begin an immune response 
towards antigen present on the surface of foreign organisms. B cells respond to antigens by 
generating proteins called antibodies, which bind a specific portion of a given antigen.  
Antibodies are an important part of the immune system as they have the capacity to detect 
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extracellular and cell surface antigens, and binding of antibodies to foreign matter activate the 
innate immune system to bind and destroy foreign organisms.[1, 3]  
Antigen response in T cells  
The ability of B cells and T cells to bind unique antigens associated with pathogens is 
due to a capacity of these cells to reorganize their DNA, an uncommon phenomenon in 
animals. The DNA of B cell receptors (BCR) and T cell receptors (TCR) is designed and 
systematically reorganized in such a way that the DNA encodes millions of possible BCRs and 
TCRs, but after reorganization only one of those possibilities is present in an individual B cell or 
T cell. Thus, when a T cell responds to antigen on an APC, the T cell is restricted to that 
antigen presented on MHC and will not recognize other antigens or the same antigen when 
unbound to MHC. [1] 
T cells require the presence of the appropriate antigen presented on MHC to begin 
activation, but more signals are needed to fully stimulate the T cell. In fact, if those other 
signals are absent, a T cell recognizing antigen on MHC may undergo death or be otherwise 
inhibited from normal activation.[3] Cytokines are one of these signals which is important to T 
cell survival and activation. Cytokines such as IL-7 and IL-15 help T cells to continue to survive 
independent of antigen. However, when T cells recognize antigen, cytokines such as IL-2, IL-4, 
IL-12, IL-17, and TGF-β can strongly influence the activation and differentiation of the T cell.[5] T 
cell naïve to antigen must receive activation through the TCR as well as costimulatory receptor 
activation. The presence of the appropriate costimulatory ligands on the APC is a crucial 
component in the activation of T cells. 
4 
 
 
Figure 1 Factors influencing T cell activation and propagation 
A) The proteins on T cells involved in transducing external signal into internal signals are 
shown. Antigen on MHC of APC stimulates TCR, costimulatory receptor detects costimulatory 
ligand on APC, and cytokine receptors detect cytokines. B) The strength of stimulation of TCR 
alone is insufficient to activate and propagate T cells. Consequently, costimulatory receptors 
and cytokines strongly influence the capacity of a T cell to propagate in response to antigen. 
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A costimulatory molecule like CD28 has the capacity to fully activate a T cell and initiate an 
immune response when CD86 is present on the APC or inhibit the T cell from responding when 
CTLA-4 prevents binding of CD28 to CD86.[6] A strong activation signal has the potential to 
promote activation, proliferation, and survival. T cells survival after infection can last many 
years and prepare the animal to respond more rapidly to a future infection of the same 
pathogen. This phenomenon of T cell survival and enhanced response is called T cell memory. 
T cell memory is clearly advantageous as many pathogens are ever-present in the environment 
of an animal, and survival depends on the ability to deter an initial infection and prevent 
repeated infections.[7]  
Natural suppression mechanisms of T cells 
T cells are quite powerful effectors of the immune system, but T cell activity can be 
deleterious if inflammation persists too long or in the absence of an actual pathogen. It is 
hypothesized that one of the evolutionary reasons for using multiple signals to fully activate T 
cells is that an inappropriately activated T cell could recognize antigens that naturally occur in 
the body of an animal. Typically T cells develop in such a way that many of these self-reactive 
T cells (T cells responding to self as though it were a foreign pathogen, also called auto-
reactive) are deleted in the thymus before the auto-reactive T cell is capable of leaving the 
thymus to target self-antigen on healthy tissues. However, some auto-reactive T cells continue 
to persist within the body usually in a state of suppressed activity.[8] While multiple mechanisms 
of immune system suppression exist, suppression mediated by a subset of T cells called 
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regulatory T cells – Treg - is considered one of the most effective means of T cell suppression 
within the body. [9] 
Tregs responds to antigen via TCR like other effector T cells (Teff) and Tcyt, but, unlike 
other T cells, the TCR of Treg is reactive towards self and induces suppression of inflammation 
when activated. While Treg previously were considered a controversial topic in immunology, 
these cells have come to be understood as critical for the maintenance of immune homeostasis 
in the body. As an understanding of Tregs developed it was found that loss of a specific 
transcription factor, FoxP3, leads to the absence of Treg and, subsequently, severe 
autoimmunity in mice and humans from an early age. Treg suppress immune responses through 
a variety of mechanisms listed in Table 1. These suppressive mechanisms each inhibit Teff and 
Tcyt function to prevent autoimmunity.[10] 
Teff, commonly called CD4+ T cells in the literature, often coordinate initiation of an 
immune response including innate immune cells and B cells, in order to remove pathogen.[3, 5] 
Teff and Treg are both CD4+ and differ from Tcyt by responding to antigen presented on class II 
MHC rather than class I MHC. Treg inhibit the inflammatory state from persisting to the point 
where it becomes deleterious. Equally, Treg inhibit Teff from initiating and propagating an 
immune response towards self-antigen which would be deleterious under healthy conditions. 
However, an immune response towards self is at times warranted in the case of somatic 
mutations that initiate and propagate cancer. In the case of cancer, Treg suppression of 
autoimmunity is deleterious as it prevents a cancer-specific immune response.[11] Clearly, the 
ratio of Teff to Treg can be crucial to the prevention of pathology. As such, many clinicians and  
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Table 1 Suppressive mechanisms of Treg 
Mediator Abbreviation Mechanism 
Adenosine  Signaling via the A2a receptor to generate cAMP[12, 13] 
3`-5` Cyclic adenosine 
monophosphate 
cAMP Inhibitory secondary signal to effector lymphocytes during 
intercellular contact.[14] 
Transforming growth 
factor - β 
TGF - β Inhibitory signaling to multiple cell types[15] 
Cytotoxic T Lymphocyte 
Antigen -4 
CTLA – 4 Inhibitory costimulation to T cells.[16] 
CD25  This portion of the IL-2 receptor is overexpressed and acts as 
a sink for the T cell activator IL-2[17] 
Interleukin-10 IL-10 Suppressive cytokine[17] 
Indoleamine – 2,3 - 
deoxygenase 
IDO Depletion of Tryptophan and arylhydrocarbon receptor 
activation[18] 
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researchers have begun to use T cell therapies to treat diseases of inflammation or immune 
suppression. 
Application of T cells in the treatment of disease 
The clearance of infections in humans requires functional adaptive immunity. Vaccines 
co-opt functional T cells and B cells to develop immunologic memory towards dangerous 
pathogens. The memory established by vaccines leads to an immune response during early 
signs of infection from a pathogen. This use of T cells and B cells has prevented an untold 
amount of morbidity and mortality related to overwhelming pathogenic infections, by early 
suppression of infection or disease pathology. The success of vaccines has motivated 
researchers to develop therapeutics for patients with dysfunctional immune responses. 
Researchers have successfully targeted immune suppression in cancer or chronic infections 
with cytokines and antibodies. This has proven quite effective in reducing the burden of many 
forms of chronic disease due to a weak immune response. In the case of an excessive immune 
response, such as autoimmunity, clinicians have also utilized cytokines and antibodies to inhibit 
the abnormal immune response.[19] With much development in the way of immunologic 
modulation, adoptive transfer of T cells remains elusive in the treatment of disease beyond a 
small number of Phase I and II clinical trials. Although these cells are crucial for mounting, 
maintaining, and suppressing an immune response, no adoptive T cell therapy has been 
formally approved for use in the United States.[20]  
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T cells to treat cancer 
Targeting T cells to human disease has been in progress for more than 25 years.[21] The 
initial aim of clinical trials was to direct T cells to target and kill diffuse cancers such as 
metastatic melanoma and leukemia.[21, 22] With the objective of targeting unusual antigens 
present only on the cancer. Antigens on cancers are often times overexpressed or mutated 
versions of proteins found on normal cells. Although cancer antigens ideally demarcate only the 
cancer, this is rarely the case and the risk of off-tumor toxicities can occur and cause serious 
complications that many times have led to morbidity and death. The powerful nature of T cell 
therapies is one of the reasons that T cells continue to be sought as a therapeutic, but have not 
yet reached FDA approval in the United States for any form of disease. 
T cell therapies are consistently improving and begun to incorporate more complex 
ideas such as transgenic modifications that perform supraphysiological actions. An early idea 
of combining the activating domain of a TCR with the antigen specificity of an antibody (Figure 
2) developed a protein called a chimeric antigen receptor (CAR) which activates a T cell 
expressing CAR when antigen is recognized on the surface of a cell.[23] This approach is 
advantageous as it extends the capacity of T cells to detect antigens not present within MHC. 
However, the risk of off-tumor toxicity continues for the same reason. CAR expression on T cell 
is a technological challenge that has improved with advances in gene therapy. Now, technical 
aspects of T cell culturing techniques and gene therapy are at a point where multiple clinical 
trials generate tumor-specific T cells or genetically-modified CAR+ T cells to target cancers.[24-26]  
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Figure 2 Comparison of chimeric antigen receptor (CAR) to TCR. 
A) The structural differences between a second-generation CAR and endogenous TCR are 
displayed with identification for each domain. B) Selective targeting of CAR to surface antigens 
independent of MHC is represented. CAR activates T cells to kill cells containing the target 
antigen, without killing cells that do not express antigen.  
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While many of the T cell clinical trials are showing strong benefit over standard of care, 
the cost of producing a T cell therapy and risk to the patient continues to hamper development 
of these technologies beyond a few specialized centers. Further limitations exist due to the 
complex immunosuppressive environment of the tumor, and difficulty of identifying appropriate 
tumor antigens.[25] It should be noted that T cell therapeutics in cancer were initially developed 
for the treatment of melanoma and leukemia, and in the intervening quarter century have not 
significantly deviated from those cancer targets. Further improvements in the technical aspects 
of T cell therapy as well as continuing research and development of immune-modulatory drugs 
will continue to promote T cell cancer therapies for cancer and potentially broaden the 
applicability of these therapeutics. 
T cells to treat infection 
A competent immune system can often develop an appropriate immune response to 
bacterial and viral antigens leading to initial clearance of the pathogen and long term immunity. 
However, not every patient has a competent immune system. In fact, patients who receive a 
transplanted organ are chronically immunosuppressed. Patients on immune-suppressive 
regimens are at risk for infection from organisms not typically pathogenic in the normal 
population. Also, viral infections, which previously led to mild and moderate illness, can be life-
threatening. This risk is most severe in the hematopoietic stem cell transplant (HSCT) setting 
where depletion of innate immune cells combines with immune-suppression to prevent MHC 
mismatching between bone marrow graft and the body of the host. High doses of 
immunosuppressive drugs put the patient at risk for viral, bacterial, and fungal infections, but 
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are necessary to prevent deadly graft versus host disease (GvHD). In this case, the appropriate 
memory T cells may not exist in sufficient quantities to fight off infection following the high dose 
chemotherapy and immunosuppression used to condition the patient for HSCT. This clinical 
need was addressed with T cell therapy, and T cells specific to viral infections began 
development more than 20 years ago. While this approach of T cell therapy has faced technical 
challenges, the risk of off-target toxicity and decreased efficacy are not as great as targeting 
cancer. T cells targeting common viral infections such as CMV, EBV, or adenovirus are up to 
Phase III clinical development at multiple institutions in the United States and at a similar stage 
in Europe.[27] 
T cells to treat inflammation 
Diseases of excessive inflammation are currently targeted by immune-modulatory or 
immune-suppressive medications. These therapies are often effective, but have untoward side 
effects as discussed in the above section. Better targeted immunosuppression may be possible 
using Tregs. As Tregs are better understood and culturing techniques become more advanced, 
cell therapies based on reconstituting Tregs will likely move toward clinical trials more rapidly. 
The use of Tregs in clinical trials has been limited to preventing GvHD following HSCT for the 
most part. It is likely that the number of uses for Treg will expand as many other forms of 
inflammation have been targeted in preclinical models. Technical challenges related to the 
isolation and propagation of Treg is currently limiting the advance of this T cell therapy.[10] 
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Selection for T cells in the treatment of disease 
A common theme in section 1.2 was the technical limitations of T cell therapies. While 
development of more effective and safer T cell therapies at times awaits an improved 
understanding of immunobiology, there is still a great deal of improvements to be made in the 
technical knowledge of T cell isolation, propagation, and re-infusion. Technical knowledge and 
expertise continues to advance the field. It often permits biological studies that advance 
knowledge as well as new and improved applications for T cell therapies.  Here we consider in 
further detail methods for the isolation and propagation of T cells. 
Antigen-specificity dependent selection (ASDS) 
The isolation of T cells based on antigen specificity can be considered an advantage of 
working with T cells. A T cell that recognizes an antigen of interest can activate and propagate 
itself to larger numbers. However, the MHC restriction of T cell antigens often limits the 
feasibility of this approach. Thus, APC must be derived from the patient, or MHC matched 
donor, to stimulate their T cells, which was the original ASDS method.[28] Methods using APC 
involves isolation and infection of donor APC with virus or activation and pulsing of antigenic 
peptide on derived APC. The infected or activated APC then presents antigen to T cells which 
activates and propagates antigen specific cells.[28] Alternatively, if the patient has a common 
MHC then other approaches are available. Artificial APCs (aAPC) made by genetically-
modifying tumor cells to express specific MHC and peptides can be used to propagate T cells 
targeting the MHC - peptide combination.[29, 30] Similarly, synthetic multimer proteins containing 
a specific MHC – peptide combination can be used to isolate T cells specific to that MHC  
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Figure 3 Common ASDS techniques for T cell selection. 
The selection of T cells using ASDS techniques occurs through three common practices. 
Shown on the left is ASDS of T cells using donor derived APC. These APCs present antigen on 
every MHC the donor expresses – hence there are 12 MHC on the donor-derived APC. In the 
center, is an artificial APC (aAPC) expressing one MHC, as aAPC are typically manufactured 
expressing one MHC. The same selective propagation of T cells is achieved by only one MHC 
peptide complex, which decreases the variety of antigen-specific T cells that are propagated. 
Similar to aAPC, on right, T cells can be selected with a multimer (seen as a tetramer), that can 
bind T cells specific to a certain MHC-peptide combination and then be purified via this method.  
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peptide combination.[31]  ASDS methods are quite effective, but are limited by the specificity of 
the TCR. Selection of T cells using APC from the same donor propagate T cells specific to 
multiple antigens of the peptide presented on multiple MHC (There are up to 12 different MHCs 
expressed by the same individual), but extracting and modifying host APC adds technical 
challenges to T cell therapy production. Artificial APC selection does not require APC 
modification for each donor, but generation of aAPC is a costly task, which results in a 
restricted array of MHC choices for presenting antigen to T cells. The use of multimer MHC 
technology does not require artificial or donor APC, but producing a multimer is a costly task 
and multimer MHC peptide complexes are typically limited to common MHC presenting a 
common peptide. Consequently, the T cells generated using aAPC and multimer MHC 
techniques target T cells to antigen within a limited population of donors and with a limited 
number of antigen targets. This restricted antigen specificity of aAPC and multimers increases 
the risk that the T cell response will be insufficient to eradicate disease. Subsequently, MHC 
restriction of T cells has become a limitation in generating T cell therapies, and many groups 
have focused on propagating cells by antigen-specificity independent selection.  
Antigen-specificity independent selection (ASIS) 
The development of MHC independent T cell propagation methods has been a great 
technical advance for T cell therapies.  Growing T cells by ASIS generates large numbers of T 
cells for reinfusion to a patient. While it might seem counterintuitive to grow T cells without 
direct selection for specificity, the large number of T cells typically includes an activated and 
propagated subset of T cells that are specific to the antigen targeted. A possible advantage 
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over ASDS is that T cells grown by ASIS may have many different types of T cells specific to 
the same disease. In the case of T cells derived from tumor, also known as tumor infiltrating 
lymphocytes (TIL), the in vivo development of multiple tumor-specific T cells led to better 
suppression of disease than a single tumor specific T cell.[32] Also, the use of ASIS permits T 
cells to be genetically modified and propagated without selection. This is commonly used in TIL 
and CAR therapies where the specificity of the T cell is not selected in vitro but once infused 
leads to ASDS within the patient.[33] The use of ex vivo expansion via ASIS and in vivo 
expansion by ASDS could be considered the current standard in T cell therapies. 
Generating T cells by ASIS requires stimulators of T cell activation and propagation 
such as stimulation, costimulation, and / or cytokine signals.[26] The propagation of T cells 
independent of MHC increases the risk for expanding deleterious T cells that might cause 
toxicity.[22] In the case of cancer, ASIS techniques propagate Treg along with Tcyt.  Consequently, 
a T cell therapeutic that is developed to target and destroy tumor may propagate cells that 
prevent T cell activity at the site of tumor.[34] On the opposite spectrum of Tcyt activity, Tcyt may 
begin to recognize antigen on healthy tissue and target vital organs for destruction.[8] These are 
just a few of the examples of poorly modulated T cell activity. The issues of poor efficacy and 
off-target toxicity are critical considerations for the field of T cell therapeutics to move forward. 
Some of the issues have biological solutions, such as the use of IL-7 or IL-15 rather than IL-2 
to decrease Treg ASIS.[26] However, other issues require a more complex approach.  
Adoptively transferred host-reactive T cells can become life-threatening when T cells 
begin to react to host antigens on vital organs. Therefore, selective depletion of adoptively 
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transferred host-reactive T cells is needed in arguably any ASIS propagated T cell therapy.[25] 
The field has found no unanimous solution to selectively deplete host-reactive T cells. Most 
groups seriously addressing this issue have determined genetic modification of T cells to be the 
most effective means to selectively deplete these cells.[35, 36] As host-reactive T cells have the 
same potential as tumor-reactive T cells to undergo ASDS in the host, an ex vivo selection 
method is needed before adoptive transfer of T cells. Transgenic CAR or TCR did not require in 
vitro selection by ASIS, as these approaches develop in vivo ASDS. However, transgenes not 
involved in direct targeting of pathology do require in vitro selection by an ASIS method. Thus, 
groups have genetically modified T cells for selective depletion in the case of host-reactivity 
using in vitro ASIS. Currently, few transgenic ASIS methods have been described to uniformly 
select a transgene. Sorting for the desired transgene co-expressed with a surface marker is the 
typical methodology with the surface marker selected using magnetic beads.[37-39]  
While magnetic bead based sorting has shown efficacy, it is time consuming and costly 
as the number of antigens to be sorted increases. Fluorescence based flow sorting techniques 
could avoid some of the technical pitfalls of magnetic sorting, but this approach is even more 
costly and time consuming.[40] Sorting cell products through large machines, possibly several 
times, increases the risk of contamination, which is a serious concern in immune-compromised 
patients receiving these therapies. It is apparent that another form of in vitro ASIS for transgene 
expression is needed. Hence, we have determined that there are technical limitations in 
transgenic selection methods, which are preventing T cell therapeutics from advancing to a 
more consistent and safe form of treatment. We have found potential methods that could be 
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modified to develop safe, non-immunogenic [41] in vitro ASIS selection for genetically modified T 
cells. Our objective is to develop in vitro ASIS methods to select for the expression of 
transgene in T cells. The long-term goal is to disseminate these approaches in order for the 
field to develop better transgenic methods to control activation, propagation, and depletion of 
genetically modified T cells in vivo. We have developed the following hypothesis for this 
purpose: 
Hypothesis 
 We find the lack of in vitro ASIS methods for T cell therapeutics to be a major limitation 
in the development of higher quality and more complex disease modifying T cell therapies. 
Novel ASIS methods are sought to enhance the selection of transgenic T cells and desirable T 
cell phenotypes. While in vitro ASIS using chimeric cytokine receptors [42] is a recently reported 
method of non-immunogenic selection, it only utilizes the third signal in T cell activation – 
cytokine signaling. We hypothesized that aAPC can complete this in vitro ASIS methodology by 
utilizing the first and second signals of T cell activation (CD3 and costimulatory signaling) of 
human genes to activate and propagate T cells independent of antigen specificity.  
Following our above argument, a single selection method (i.e. surface-expressed 
marker) is limiting the development of more advanced T cell therapeutics. Hence, we sought 
another in vitro ASIS method independent of surface-expression. The original in vitro ASIS 
techniques, selection with toxic drug by expressing a drug resistance transgene,[43, 44] suffered 
from the immunogenicity of the transgene origin – bacteria.[45] Here we hypothesize that the 
19 
 
lower immunogenicity of mutated human transgenes will establish resistance to anti-
thymidylate drugs as a new in vitro ASIS method. This method will have the advantage of 
potentially allowing for in vivo ASIS to a whole class of FDA approved drugs.[46]  It is our overall 
hypothesis that these non-immunogenic in vitro ASIS techniques will guide development of 
better in vitro and in vivo ASIS of T cell phenotypes such as Treg, Teff, or Tcyt and the capacity to 
better control the activity of the T cell.  
Specific Aims 
Specific Aims 1 
 We sought an AaPC that could select for and propagate T cells independent of antigen 
specificity by targeting a conserved exo-domain of CAR+ T cells. This AaPC would ligate and 
propagate T cells through CAR independent of antigen specificity.  
Specific Aims 2 
 We determined that transgenic selection with toxic drug would best be achieved with 
non-genotoxic drugs. The thymidine synthesis pathway was targeted as it is well described, 
non-genotoxic, and often used clinically to suppress T cell proliferation and cancers. Two 
enzymes in the thymidine synthesis pathway, dihydrofolate reductase (DHFR) and thymidylate 
synthase (TYMS) have an entire class of drugs designed to target these enzymes. We 
developed anti-thymidylate resistant mutants of DHFR and TYMS to achieve in vitro ASIS of 
transgenic T cells. 
Specific Aims 3 
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 Utilizing the transgenic in vitro ASIS techniques above, we sought a novel ASIS method 
to select for or against Tregs. We dissected the T cell suppressive effects of the anti-thymidylate 
methotrexate (MTX) to develop a drug-based method for selecting Treg. This improved 
understanding of Treg physiology led to the finding that a common antibiotic drug class - 
aminoglycosides - depletes Treg. Hence, transgenic in vitro ASIS techniques advanced the 
understanding of selection for T cell phenotypes  
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CHAPTER 2: In vitro ASIS of CAR+ T cell for testing and clinical 
expansion using aAPC 
This chapter is presented without substantial modification from the following publication: 
Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee D, Cooper LJ: 
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric 
antigen receptor independent of specificity. Journal of immunotherapy 2014, 37(4):204-213. 
The Journal of Immunotherapy has given permission to republish this work here 
Introduction: 
The adoptive transfer of antigen-specific T cells is a rapidly developing field of cancer 
immunotherapy with innovative approaches to their manufacture being tested and new 
antigens being targeted. T cells can be genetically-modified for immunotherapy to express 
chimeric antigen receptors (CARs) that recognize tumor-associated antigens (TAAs) 
independent of HLA (editorial note: HLA is the human version of MHC) expression. Recent 
results from early-phase clinical trials demonstrate that CAR+ T-cell (CART) therapies can lead 
to partial and complete remissions of malignant diseases, including in some recipients with 
advanced/relapsed B-cell tumors.[47, 48]  
Currently, many CART therapies are based upon ex vivo propagation from the donated 
T cells obtained from steady-state apheresis or venipuncture.[49-54] Approaches for numeric 
expansion typically use either CAR-independent T-cell proliferation based upon cross-linking 
CD3 and CD28 with antibodies[50-52, 55] or CAR-dependent propagation using TAA expressed on 
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artificial antigen presenting cells (aAPC).[56-59] Other methods to selectively propagate T cells to 
constitutively express CAR include co-expression with transgenes for selection under cytocidal 
concentrations of drug and/or sorting, such as using magnetic beads that recognize introduced 
proteins co-expressed with CAR.[56],[37] After electro-transfer of DNA plasmids derived from 
Sleeping Beauty (SB) system, we employ CAR-mediated expansion to selectively propagate T 
cells that stably express the introduced single-chain immunoreceptor by repeated additions of 
γ-irradiated K562 cells genetically modified to co-express costimulatory molecules and the TAA 
targeted by the introduced CAR.[49, 57, 60] However, this necessitates that each aAPC design 
must be manufactured to express the TAA targeted by a given CAR. Furthermore, some TAA 
that are biochemically or structurally complex, such as glycosphingolipids, are difficult to 
recapitulate on the surface of aAPC.[61]  
Here, we describe an approach to achieve CAR-mediated expansion that avoids the 
requirement for cytotoxic drugs, magnetic selection, or TAA-specific proliferation. A monoclonal 
antibody (mAb, clone 2D3), previously reported by our laboratory, [57] was shown to bind to the 
conserved exodomain (derived from modified human hinge and Fc region of IgG4) [62] of a 
CAR. The antigen-specificity of this mAb was constructed as a single-chain variable fragment 
(scFv) and expressed on K562 cells to serve as an aAPC.[49, 63] This scFv on the cell surface of 
aAPC is able to ligate a panel of CARs with diverse specificities that contain the IgG4 
extracellular scaffold, leading to selective expansion of genetically modified T cells that have 
redirected specificity for multiple TAAs. This scFv serves as a ligand for CAR (designated 
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CARL) that can substitute for TAA and thus provides investigators with one source of aAPC 
that may be used to generate populations of CAR+ T cells with any specificity.  
Materials and Methods: 
Cells and culture conditions 
K562 cells (European Collection of Cell Cultures through Sigma-Aldrich, St. Louis, MO; 
Cat. No. 89121407), noted for expression of desired endogenous adhesion molecules and the 
absence of most HLA class I and all class II molecules, [63] were used to derive CD19+ and 
CARL+ K562 that served as aAPC. Immortalized tumor targets CD19neg, GD2+ EL-4 murine 
thymoma (Cat. No. TIB-40) and CD19+, GD2neg NALM-6 (pre-B cell leukemia, Cat. No. CRL-
1567) were purchased from American Type Culture Collection (ATCC, Manassas, VA). Identity 
of cell lines was validated by the MDACC Cancer Center Support Grant Characterized Cell 
Line Core using short tandem repeat DNA fingerprinting. Peripheral blood was donated by 
consenting healthy volunteer adults at Gulf Coast Regional Blood Center (Houston, TX). 
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Paque Plus density 
centrifugation (GE Healthcare Biosciences, Piscataway Township, NJ; Cat. No. 17-1440-02) 
before freezing in a mixture of 10% DMSO (Sigma, Allentown, PA; Cat. No. D2650), 50% heat-
inactivated fetal bovine serum (FBS-Thermo Scientific Hyclone, Bridgewater, NJ, Cat. No. 
SH30070.03), and 40% RPMI 1640 (Thermo Scientific Hyclone; Cat. No. SH30096.01). All 
cells were cultured in a 37º C humidified incubator with complete media (CM) prepared from 
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RPMI 1640, 10% heat-inactivated FBS, and 2 mM GlutaMAX supplement (Life Technologies, 
Grand Island, NY; Cat. No. 35050061).  
DNA expression plasmids 
Codon-optimized CD19RCD28mZ (CoOp)/pSBSO, [57] which codes for CAR between 
transposition sites mediated by SB transposase, [64] was used as the vector backbone for 
cloning of the following transgenes. The DNA plasmid 19G4CAR (also designated 
CD19RCD28, [65] Figure 4A) codes for a 2nd generation CD19-specific CAR containing a 
modified IgG4 exodomain, CD28 transmembrane, and CD28/CD3ζ endodomain. The synthesis 
of DNA plasmid GD2G4CAR (Figure 4B), specific to sphingolipid GD2, utilized the same 
19G4CAR backbone. The GD2-specific scFv derived from murine mAb (clone 14G2a) [66] was 
commercially synthesized (Geneart, Life Technologies) as codon-optimized cDNA with NheI 
and XmnI restriction enzyme (RE) sites flanking the scFv. The 19G4CAR plasmid backbone 
and GD2-specific scFv cDNA were excised using these REs and ligated to replace CD19-
specific scFv with GD2-specific scFv. A DNA plasmid (Figure 4C) coding for a control CAR that 
contains no scFv region, designated G4CAR, but does contain an Igκ-FLAG peptide sequence 
(METDTLLLWVLLLWVPGSTGDYKDEGTS), was derived from 19G4CAR using primer-
directed PCR amplification from the beginning of the IgG4 domain hinge (primer 
5’GGTACCTCTGGGGGGCAGGGCCTGCATG3’) to the terminus of the CD3 domain (primer 
5’GGGCCCAGCGCTGAGAGCAAGTACGGCCCTCCC3’) and sequence verified. The G4CAR 
was ligated into the 19G4CAR backbone ApaI and KpnI RE sites. DNA plasmid coding for a 
CD19-specific CAR with no IgG4 (Figure 4D), designated 19CAR, encodes from amino to 
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carboxyl termini a GM-CSF (amino acid 1-22; NP_758452.1), CD19-specific scFv (245 amino 
acids), CD8α extracellular domain and hinge (amino acids 136-203; NP_001759) followed by 
the same CD28 transmembrane and CD28 and CD3ζ domains as other CARs.[65] The full 
length of this transgene was synthesized by GeneArt, cut with ClaI and SpeI REs, and ligated 
into the 19G4CAR backbone replacing the 19G4CAR codon, which had been excised using 
EcoRV and SpeI. The scFv sequence of CARL was derived from the cDNA library of the 2D3 
hybridoma.[57] This was achieved by extracting RNA from 5x106 cells using the RNeasy Mini Kit 
(Qiagen, Gaithersburg, MD; Cat No. 74104) according to manufacturer’s protocol. A cDNA 
library was generated by reverse transcription using oligo-dT primers per the protocol provided 
in the Superscript III First Strand kit (Invitrogen; Cat No. 18080-051). PCR (using Amplitaq 
Gold) was performed on the cDNA using the degenerate primers for the FR1 region [67] to 
amplify the mouse VH and VL regions. The VH and VL amplified products were ligated into the 
TOPO TA vector and sequenced. The CARL construct for surface expression on aAPC was 
composed of GM-CSF leader peptide (amino acid 1-22; NP_758452.1) fused to  the 2D3-
derived scFv, and tethered by CD8α (amino acid 136-182; NP_001759.3) to the 
transmembrane and intracellular portions of CD28 (amino acid 56-123; NP_001230006.1) 
followed by CD3ζ (amino acid. 48-163; NP_ 000725.1) intracellular domain. Design of all 
transgenes utilized Vector NTI Advance™ 11 software (Invitrogen). All transgenes were human 
codon optimized before synthesis at GeneArt. The CARL construct was excised and ligated 
into a SB expression plasmid, designated Zeo-2A-CARL (Figure 4E), to co-express a zeocin 
resistance gene linked via a modified T2A peptide sequence- (amino acids  
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Figure 4 Vector maps for expression of transgenes. Each DNA plasmid expresses a transgene 
of interest under promoter human Elongation Factor 1 alpha (phEF-1α), using the beta 
hemoglobin poly-adenylation signal (BGH) to terminate transcription. The indirect repeats / 
direct repeats (IR/DR) allow for transgene transposition into the genome using SB11. All 
plasmids were propagated in bacteria using the origin of replication ColE1 and Kanamycin 
resistance (KanR) under the promoter pKan. A) 19G4CAR demonstrates the original plasmid 
design used in these studies and shows NheI and XmnI restriction enzyme (RE) sites used to 
generate B) GD2G4CAR from PCR-directed truncation of CD19-specific scFv on 19G4CAR 
which led to the generation of C) G4CAR and final ligation using ApaI and KpnI REs. D) 19CAR 
was designed without an IgG4 exodomain, instead expressing the CD8α hinge and exodomain. 
E) Zeo-2A-CARL, expressing CARL, and F) CD19-2A-Neo, expressing truncated human CD19 
(tCD19), were designed to express CARL or CD19 on aAPC under drug selection conditions. 
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ATGEGRGSLLTCGDVEEPGP). Truncated human CD19 was synthesized by GeneArt 
containing the extracellular and transmembrane portions of human CD19 (amino acid 1-313; 
NP_001171569.1). This gene was excised and ligated into SB DNA plasmid, designated CD19-
2A-Neo (Figure 4F), to co-express with neomycin phosphotransferase linked via a modified 
F2A peptide sequence (amino acids (G)4S(G)4SVKQTLNFDLLKLAGDVESNPGP). 
Artificial antigen presenting cells (aAPC)  
CARL+ and CD19+ aAPC were derived by the independent electroporation of parental 
K562 cells with Zeo-2A-CARL or CD19-2A-Neo and SB11 transposase DNA plasmids using 
the Amaxa 2D nucleofector under program T-16 with Kit V (Lonza, Allendale, NJ; Cat No. VCA-
1003). After 3 days incubation, each transfection was placed under drug selection in a 6-well 
plate using either 0.5 mg/mL Zeocin or 1 mg/mL G418 for Zeocin resistance or Neomycin 
resistance, respectively (Invivogen, San Diego, CA; Cat. No. ant-zn-1 and ant-gn-1). This was 
achieved by dispersing 10,000 cells with drug in 3 mL semi-solid Methocult H4230 media 
(StemCell Technologies, Vancouver, BC, Canada; Cat No. 04230). After 10 days visually-
perceptible individual (clonal) colonies were transferred to individual flasks and grown in CM. 
Each clone was tested for uniform expression of CARL or CD19 using flow cytometry. Clones 
of CARL+ (designated Zeo-2A-CARL MC5) and CD19+ (designated CD19-2A-Neo MC2) aAPC 
were grown to large numbers, γ-irradiated at 100 cGy, and cryopreserved. Before freezing, the 
aAPC were routinely tested for the presence of transgenes, absence of mycoplasma, and 
absence of endotoxin.  
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Propagation of CAR+ T cells (CART) 
The designs of each CAR and antigen (CARL and CD19) as expressed on the 
respective T cell or aAPC are shown in Figure 5A. The propagation of CART is depicted in 
Figure 5B. Each CAR from Figure 5A.II was co-cultured with aAPC from Figure 5A.I. At the 
initiation of the experiment (defined as Day 0), thawed PBMC were washed twice, and 
maintained in CM for 3 to 4 hours before electroporation using the Amaxa 2D Nucleofector 
under program U-14 with human T cell Nucleofector kit (Lonza Biosciences; Cat No. VPA-
1002). After resting overnight in CM, viable PBMC (counted by exclusion of 0.1% Trypan Blue) 
were resuspended in CM and mixed at a 1:2 ratio (mononuclear cell to γ-irradiated aAPC) using 
thawed aAPC that were washed twice and counted. The co-culture contained 106 total cells/ 
mL in CM and 50 IU/mL recombinant human IL-2 (Proleukin, Prometheus Labs, San Diego, 
CA). The live-cell counts were determined by Trypan Blue exclusion on Days 1, 7, 14, and 21 
of co-culture. Flow cytometry for CD3, CD4, CD8, and human IgG (to assess CAR expression) 
occurred on Days 1, 7, 14, and 21, and for CD45RO, CD62L, and CD28 occurred on Days 14 
and 21. Irradiated aAPC were re-added to co-cultures on Days 7 and 14 by re-stimulating 
mononuclear cells with γ-irradiated aAPC at 1:2 ratio. On Day 21 products of propagation were 
assessed for specific killing, and DNA and RNA were extracted. Each experiment was repeated 
at least 4 times using 5 donors. 
Flow cytometry 
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We used a FACSCalibur (BD Biosciences, Billerica, MA) to acquire samples prepared 
in FACS staining solution as previously described.[68] After washing once in FACS staining 
solution, cells were stained for 30 minutes at 4º C without blocking in FACS staining solution 
containing a 1:33 dilution of antibody. When anti-human Fc antibody was used, the anti-Fc 
stained sample was washed and re-stained for alternative surface markers before re-
suspension in FACS buffer for flow cytometer analysis. Measurement of intracellular cytokine 
used the same protocol for cell surface staining followed by 20 min. fixation using BD 
cytofix/cytoperm kit fixative (BD Biosciences; Cat No. 554714), followed by washing twice in 
perm/wash buffer containing 20% FBS and staining with a 1:33 dilution of antibody in 
perm/wash buffer. Antibody incubation lasted 30 minutes at 4ºC before samples were washed 
in perm/wash buffer and resuspended in FACS staining solution for acquisition. FlowJo v 
10.0.5 (Tree Star Inc., Ashland, OR) was used for analysis of flow cytometry data. See Table 2 
for antibodies used.  
Chromium release assay (CRA) 
CRA was performed as previously described.[57] In brief, on Day 21 of T-cell co-culture 
on aAPC, the tumor targets (i) EL-4, (ii) NALM-6, and (iii) K562 were loaded with 51Cr for 3 
hours, and, after washing, co-cultured with effector T cells for 6 hours at 37º C using a ratio of 5 
T cells to 1 target cell.  
Abundance and diversity of TCR repertoire  
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The direct TCR expression assay (DTEA), as previously reported,[69] was used to 
measure the abundance of mRNA transcripts coding for 45 TCR α alleles, 46 TCR β alleles, 13 
TCR γ alleles, and 5 TCR δ alleles from RNA obtained on Day 0 (T cells in PBMC before 
electroporation) and Day 21 (from T cells after electroporation/ propagation). Day 0 samples 
were negatively sorted for CD56 (Miltenyi Biotec, Cambridge, MA; Cat. No. 130-050-401) and 
then positively sorted for CD3 (Miltenyi Biotec; Cat. No. 130-050-101). The resulting 
CD3+CD56neg T cells (2 to 3 x 106 from each sample) were snap frozen as were 2 x 106 cells 
directly harvested at Day 21 of co-culture. RNA was extracted from thawed samples using the 
ALLprep DNA/RNA mini kit (Qiagen; Cat. No. 80204). 
Statistics 
Statistical analysis was performed using Prism v6.0 (Graph Pad Software Inc.). 
Student’s t-test (unpaired) was used to perform two sample comparisons. One- or two-way 
ANOVA F–test was used to perform group comparisons, and if found significant (p < 0.05); a t-
test (unpaired) was undertaken to assess and report differences. Spearman’s nonparametric 
correlation was performed on housekeeping gene normalized DTEA transcript counts to assess 
the divergence of the TCR repertoire in T cells from an experimental group and autologous Day 
0 PBMC. If the Spearman correlation coefficient was greater than or equal to 0.8 (ρ ≥ 0.8) 
within the 95% confidence interval of the correlation coefficient, then the two TCR repertoires 
were considered to be highly correlated.  
Results: 
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Figure 5 
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Figure 5: Study design to compare ability of chimeric antigen receptor (CAR) ligand (CARL) 
versus CD19 TAA on K562 cells for the selective propagation of CAR+ T cells (CART). A) 
Artificial antigen presenting cells (aAPC) demonstrated in I) were derived from parental K562 
cells following transgene transfer, stable integration, and clonal selection. Each aAPC clone 
expresses either CARL, a scFv derived from 2D3 mAb that binds IgG4 exodomain of CAR, or 
truncated human CD19. II) CART used to evaluate specificity towards CARL or CD19 are 
shown. SB-derived DNA plasmids coding for a panel of CARs were individually electro-
transferred into PBMC and recursively stimulated with CD19+ K562 or CARL+ K562 in the 
presence of soluble recombinant human IL-2. Each CAR follows a modular design. 19G4CAR 
contains the IgG4 scaffold and targets CD19 through the same scFv as 19CAR which lacks 
IgG4 scaffold and instead uses CD8α hinge and extracellular domain. GD2G4CAR contains the 
IgG4 scaffold and targets GD2. G4CAR contains the IgG4 scaffold, but has no scFv. All CARs 
employ of a 2nd generation design containing CD28 and CD3 signaling endodomains. B) On 
Day 0, synchronous electroporation of PBMC was undertaken with DNA plasmid coding for SB 
transposase (SB11- green) and SB DNA plasmids coding for CAR species (orange). To 
achieve outgrowth of T cells stably expressing CARs, the genetically modified cells were co-
cultured, beginning on Day 1, upon γ-irradiated CD19+ or CARL+ K562 in the presence of 50 
IU/mL IL-2. Cytokine was added with stimulation or during media change. Re-stimulation of 
CAR with aAPC occurred every 7 days until Day 21. C) Diagram of docking between CARL+ 
K562 cells and 19G4CAR+ T cells as compared with CD19+ K562 cells with 19G4CAR+ T cells. 
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Table 2 Fluorochrome-conjugated antibodies used for flow cytometry. 
Antibody Vendor Catalogue number 
mouse anti-human Fc-PE* Invitrogen Cat. No. H10104 
CD3-FITC BD Cat. No. 349201 
CD4-APC BD Cat. No. 340443 
CD8-PerCP-Cy5.5 BD Cat. No. 341051 
CD28-PerCP-Cy5.5 BD Cat. No. 337181 
CD45RO-APC BD Cat. No. 559865 
CD62L-PE BD Cat. No. 555544 
IL-2-APC BD Cat. No. 554567 
IL-4-PE BD Cat. No. 340451 
Ifn-γ-FITC BD Cat. No. 554700 
goat anti-mouse Fab-
FITC** 
Jackson Immunoresearch Cat. No. 555415 
CD19-APC BD Cat. No. 555415 
*Used to detect CAR containing IgG4 exodomain; ** Used to detect CARL 
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Numeric expansion of CAR+ T cells upon K562 cells expressing CARL or CD19  
Mouse mAb clone 2D3 was obtained by repeated footpad injections of NSO cells expressing 
19G4CAR into BALB/c mice and blocking studies defined the specificity of the mAb to the 
human IgG4 exodomain of 19G4CAR.[57] We hypothesized that this mAb may be used to cross-
link CAR and activate genetically modified T cells for sustained proliferation. Therefore, the 
scFv of 2D3 (designated CARL) was expressed on the cell surface to compare with human 
truncated CD19 TAA on K562 cells. The CARL and CD19 transgenes were cloned into DNA 
plasmids for co-expression with drug-selection genes between SB transposable elements. The 
SB transposon DNA plasmids for 2D3-derived scFv or CD19 were electro-transferred with 
SB11 transposase DNA plasmid into K562 cells in separate experiments. Genetically modified 
cells were propagated under drug selection from a single cell for homogeneous expression of 
CARL (as detected by antibody against mouse Fab) or CD19 (Figure 6A). A comparison of the 
γ-irradiated K562-derived aAPC to selectively propagate CART was undertaken following 
electroporation (defined as Day 0) of the panel of CAR constructs (Figure 5A.II) into PBMC 
using SB system. On Day 1, initial expression of CAR in T cells was evaluated by flow 
cytometry using antibody specific for human Fc (Figure 6B). The expression of CARs and 
number of total viable T cells were measured weekly for 21 days of co-culture with CD19+ K562 
or CARL+ K562 with the following immunoreceptors on T cells; (i) 19G4CAR with specificity for 
CD19 and containing the IgG4 exodomain, (ii) 19CAR with specificity for CD19 and absence of 
IgG4 exodomain, (iii) G4CAR without scFv, but containing an IgG4 exodomain, and (iv) 
GD2G4CAR with specificity for GD2 and containing the IgG4 exodomain. All CAR species  
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Figure 6 
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Figure 6: Characterization of aAPC and CAR+ T cells. A) CD19 and CARL as SB transposons 
were integrated into parental K562 cells using SB11 transposase and clonally expanded for 
homogeneous expression of CD19 or CARL. Dot plots depict the expression of CD19 and 
CARL on parental K562 and derived clones. The stable expression of CARL is shown using 
antibody that detects mouse Fab. B) The expression level of CAR species as determined by 
flow cytometry is shown on Days 1 and 21 of co-culture with aAPC. Expression of chimeric 
IgG4 revealed CAR expression in all constructs except 19CAR which was determined using an 
antibody against human Fc. The percentage of cells in each flow plot quadrant is provided as 
an inset. C) The effect of aAPC design on abundance of CAR expression was assessed on 
Day 21 by measuring mean fluorescent intensity (MFI) of IgG4 signal by flow cytometry. The 
experiments are designated [CAR & aAPC] with unmodified mock electroporated T cells (No 
DNA plasmid) used as a control. Each experimental group contained 4 or 5 separate donor-
derived PBMC. Statistical comparison was undertaken by One-way ANOVA followed by 
unpaired t-tests between each experiment (* = p < 0.05).  
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contained the same transmembrane and intracellular domains (CD28/CD3ζ) as the 2nd 
generation 19G4CAR.[57] The co-cultures of CART with the two types of aAPC were found to 
have significantly different amounts of T cells by Day 21 depending on the choice of aAPC (p < 
0.05) using two-way ANOVA followed by un-paired t-tests. The 19CAR+ T cells proliferated 
upon co-culture with CD19+ K562 and G4CAR+ T cells proliferated upon co-culture with CARL+ 
K562 in an exponential fashion, whereas 19CAR on CARL+ K562 and G4CAR on CD19+ K562 
did not numerically expand (Figure 7A top panel).  
These data indicate that, as expected, the CD19 TAA on aAPC selectively supports the 
outgrowth of CD19-specific CART. Furthermore, they demonstrate that CARL can activate T 
cells to proliferate that contain a CAR species with an IgG4 exodomain. Next, the ability of 
CD19+ K562 and CARL+ K562 were assessed for ability to sustain the proliferation of T cells 
expressing 19G4CAR to evaluate how two modes of crosslinking (Figure 5C) can activate T 
cells. There were no significant differences in the accumulated number of viable T cells on Day 
21 of co-culture based on the type of aAPC used (Figure 7A bottom panel), the expression of 
CAR as a percent of the population (Figure 7B bottom panel), or the mean fluorescence 
intensity (MFI). A trend (p = 0.09) towards a difference in MFI of CAR expression resulting from 
aAPC employed to expand 19G4CAR was noted (Figure 6C). There were no significant 
differences (Figure 7C & D) between the two aAPC types for propagating 19G4CAR+ T cells 
co-expressing cell-surface proteins associated with memory phenotype (p = 0.82),[70] or other 
co-receptors (p = 0.26), as well as the specific lysis by 19G4CAR+ T cells (p = 0.16). Therefore,  
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Figure 7 
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Figure 7: Comparison of CAR+ T cells propagated on CD19+ or CARL+ aAPC. A) Total inferred 
T-cell number and B) CAR (IgG4) expression for each CART was measured every 7 days for 5 
donors. Top panel: 19CAR+ or G4CAR+ T cells were numerically expanded on either CD19+ or 
CARL+ aAPC. Bottom panel: 19G4CAR+ T cells were propagated on either CD19+ or CARL+ 
aAPC. C) After 21 days of co-culture on CD19+ or CARL+ aAPC, 19G4CAR+ T cells from 5 
donors were assessed for expression of markers associated with memory (top panel) or T cell 
co-receptors (bottom panel). D) Specific killing by electroporated/propagated T cells expressing 
19CAR, G4CAR, and 19G4CAR, by CRA at a ratio of 5 effectors to 1 target. The tumor targets 
were EL-4 (murine thymoma- GD2+, CD19neg), NALM-6 (human B cell ALL- GD2neg, CD19+), 
and K562 (a human CML- GD2neg, CD19neg). Up to 5 donors were tested in 4 independent 
experiments. ns- No significance, * = p<0.05, *** = p<0.001 
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CD19-specific CAR+ T cells can be propagated in similar quantity and quality by K562-derived 
aAPC expressing CAR or CD19.  
CARL+ K562 can numerically expand CAR+ T cells independent of specificity  
The 2D3-derived scFv on aAPC was evaluated for ability to propagate not just CD19-
specific T cells, but CAR+ T cells of alternative specificities. The CD19 and GD2 [71] TAAs are 
not present on parental K562 cells to propagate T cells expressing GD2G4CAR, 19G4CAR, 
and G4CAR. Nonetheless, T cells bearing these three CARs numerically expanded on CARL+
 
K562. The number of total viable T cells on Day 21 of co-culture with CARL+ K562 cells did not 
significantly differ between 19G4CAR, G4CAR, and GD2G4CAR (p = 0.16, Figure 8A). 
Similarly, the percentage of each CAR expressed on T cells at Day 21 did not significantly differ 
among the three populations of genetically modified T cells (p = 0.68, Figure 8B). Finally, the 
electroporated and propagated T cells exhibited specific lysis of CD19 and GD2 TAAs 
recognized by CD19-specific and GD2-specific CARs. EL-4 cells, previously reported to 
express GD2, [66] were specifically killed by GD2G4CAR+ T cells and not with T cells expressing 
G4CAR or 19G4CAR. As anticipated, CD19+ NALM-6 cells were targeted by T cells expressing 
19G4CAR (Figure 8C). In summary, genetically modified T cells can be selectively propagated 
by CARL+ K562 cells resulting in T cells that retain specificity for TAA and stable expression of 
CAR.  
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Figure 8 
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Figure 8: Numeric expansion of CAR+ T cells using CARL+ aAPC. A) Total inferred T-cell 
number and B) CAR (IgG4) expression for each CART was measured every 7 days from 4 to 5 
donors for 21 days of co-culture on aAPC. The differences between Day 21 total T-cell number 
and percent CAR expression was assessed using One-way ANOVA. C) The specific killing by 
panel of T cells expressing GD2G4CAR, 19G4CAR, and G4CAR, were tested using CRA at a 
ratio of 5 effectors to 1 target. The targets were EL-4 (GD2+, CD19neg), NALM-6 (GD2neg, 
CD19+), and parental K562 (GD2neg, CD19neg). Two-way ANOVA followed by unpaired t-tests 
was performed for 4 to 5 donors tested in 4 independent tests on Day 21 of co-culture on 
aAPC. ns- No significance, * = p<0.05. 
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The choice of aAPC does not skew the TCR repertoire for numerically expanded CART 
Each T cell in peripheral blood bears a distinct pair of αβ or γδ TCRs which can be 
analyzed using the direct TCR expression assay (DTEA) to determine the abundance of TCR 
chains. This assay was employed to determine whether CARL+ or CD19+ K562 influenced the 
distribution of TCR alleles after 21 days co-culture on aAPC. TCR variants were assayed on 
the nCounter Analysis System using a set of 111 TCR α, β, γ, and δ transcripts.[68, 69] By 
measuring the distribution of TCR alleles we could determine if the aAPC design preferentially 
supported the numeric expansion of some, but not all genetically modified T cells. The starting 
TCR distribution of T cells on Day 0 was ranked from the most to least frequent TCR usage 
and the rank order compared for T cells harvested on Day 21 of co-culture with aAPC (Figure 
9A). This revealed no apparent monoclonal or oligoclonal outgrowth of electroporated T cells 
propagated on CARL+ or CD19+ K562 cells. The ranks of TCR frequencies on Day 0 and Day 
21 from each experiment were compared using Spearman’s rank correlation test and found to 
significantly correlate (p < 0.0001; Table 3). The statistical comparison of TCR abundance and 
type from Day 0 and 21 indicated that all correlation coefficients (ρ) had values greater than 0.8 
within the 95% confidence interval of ρ which is consistent with a strong correlation, indicating 
no change in TCR frequency. The measurement of TCR abundance demonstrates that CARL 
or TAA on aAPC do not skew the outgrowth of sub-populations of propagated T cells, but 
rather that both 2D3-derived scFv and CD19 on K562 cells can sustain the outgrowth of CAR+ 
T cells that maintain a polyclonal repertoire. 
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Figure 9 
Figure 9: Comparison of TCR repertoire changes induced by CAR-mediated expansion on 
aAPC. A) TCR repertoire was measured for 111 TCR α, β, γ, and δ alleles using DTEA. [69] 
TCR abundance was organized from the most to the least frequently occurring transcripts 
based on sorted CD3+CD56neg cells from Day 0. The set is visually represented next to TCR 
repertoire expressed by T cells at Day 21 of co-culture on CARL+ K562 cells and CD19+ K562 
cells. Analysis was performed on 2 donors and a representative plot of one donor is shown.   
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Table 3 Comparison of TCR abundance harvested from T cells before versus after 
propagation on aAPC* 
Day   0 
 
 21 
 
 
 
 19G4CAR & 
CARL+ K562    
 
G4CAR &  
CARL+ K562 
GD2G4CAR &  
CARL+ K562 
19G4CAR &  
CD19+ K562 
 0    0.748  
(0.65-0.82) 
0.857  
(0.80-0.90) 
0.867   
(0.81-0.91) 
0.912  
(0.87-0.94) 
19G4CAR & 
CARL+ K562 
0.752 
(0.65-0.83) 
 0.805  
(0.72-0.86) 
0.706   
(0.59-0.79) 
0.734  
(0.63-0.81) 
G4CAR &  
CARL+ K562 
0.899 
(0.85-0.93) 
0.71  
(0.61-0.79) 
 0.816  
(0.74-0.87) 
0.839  
(0.77-0.89) 
GD2G4CAR & 
CARL+ K562 
0.825 
(0.75-0.88) 
0.72  
(0.61-0.80) 
0.801  
(0.72-0.86) 
 0.881  
(0.83-0.92) 
 21 
 
19G4CAR &  
CD19+ K562  
0.916 
(0.87-0.94) 
0.69   
(0.57-0.78) 
0.887  
(0.84-0.92) 
0.808  
(0.73-0.87) 
 
 
*Analysis DTEA data from two donors was normalized using housekeeping genes and 
assessed using Spearman correlation coefficient to compare distributions of TCR usage for two 
donors. The upper right of the table contains the correlation between experimental groups for 
one donor. The lower left of the table contains the second donor subjected to the same 
analysis. Each cell in the table contains the Spearman correlation coefficient (ρ) and within the 
brackets the 95% confidence interval. (A strong correlation is considered to be ρ ≥ 0.8.) 
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Discussion 
This study demonstrates that a ligand directed against a conserved extracellular domain 
on CARs can function to numerically expand CART while preserving redirected specificity of 
genetically modified T cells for TAA. This differs from other methods to select or sort for CART 
such as magnetic sorting, [37] selection with cytotoxic drug, [56] or TAA-mediated numeric 
expansion. A recent report demonstrated antigen-independent CAR-mediated T-cell activation 
using antibody binding to an extracellular Myc-tag of ErbB2-specific T cells.[72] Our study differs 
as CARL recognizes a determinant native to an extracellular scaffold to induce proliferation of 
CART. This provides an apparent advantage, as the use of epitope tags may alter antigen 
recognition or increase immunogenicity. Our data demonstrate that a mAb-derived scFv 
sequence directed against conserved extracellular CAR domains can be used for cross-linking, 
activation, and propagation of CAR species on genetically modified T cells.[50-52] Thus, CARL-
mediated numeric expansion of CART will be useful to laboratories seeking to augment the 
selective outgrowth of CART within a tissue culture environment after gene transfer.  
A benefit of our approach is that one CARL design could functionally substitutes for 
multiple TAAs. Specifically, the CARL in this report enables K562 cells to function as aAPC to 
propagate T cells expressing a panel of CARs to specifically lyse tumor cells expressing 
multiple TAAs. Alternatively, our technology allows for CARs to be designed which impart no 
specificity. This was demonstrated here as a proof-of-concept with G4CAR activating T cells to 
proliferate during co-culture with CARL+ K562 cells without ligating endogenous CD3. Implicit in 
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this finding is that any T cell bearing an introduced CAR, or other immunoreceptor containing 
the CARL-binding domain, may be propagated upon cross-linking by CARL.  
Recent studies have demonstrated that reducing the length of an IgG4 exodomain 
improved cytokine secretion, cytotoxicity, and proliferation of ROR1-specific CART [73] and 
removal of IgG1 scaffold from a CAR appeared to improve killing of CD22+ targets.[74] These 
improvements in potency support modifying the scFv distance from the T-cell membrane to 
enable a candidate CAR design to provide a fully-competent T-cell activation signal. The 
identification of the peptide recognized by 2D3-derived scFv is ongoing, and may enable us to 
alter the length of the extracellular domain to tune CAR+ T cells for optimal activation by TAA 
while preserving the ability of CARL to propagate genetically modified T cells.  
One measure of redirected specificity is the ability of CAR to mediate T-cell killing of 
TAA+ targets. The cytotoxicity of CARL-propagated CART appears to be moderately reduced 
based on prior publications.[64, 75] This may be accounted by the design of the CARL+ and 
CD19+ aAPC, which were not engineered to express costimulatory molecules such as CD86, 
CD137L and membrane-bound IL-15, as are present on aAPC (designated clone 4) we 
previously used to generate CD19-specific 19G4CAR+ T cells.[49]  Furthermore, we used aAPC 
clone 4 in the presence of soluble recombinant IL-2 and IL-21 whereas CARL+ K562 cells were 
co-cultured with genetically modified T cells with only IL-2. Future studies will help elucidate the 
effect of costimulation on CART performance.  
It is possible that the aAPC used to activate CAR may selectively propagate a sub-
population of genetically modified T cells over the co-culture period. However, we observed 
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that both CARL+ and CD19+ K562 cells numerically expanded T cells bearing a similar 
percentage expression and density of CAR, a comparable immunophenotype. In addition, there 
were no significant differences in TCR repertoire expression and abundance before versus 
after propagation on aAPC indicating that the starting population of T cells matched the 
population present at the end of the co-culture period. These findings justify investigating 
whether CARL+ aAPC might be used to generate CART for human application. Furthermore, it 
is our expectation that expression of CARL on a single source of clinical-grade aAPC can be 
used to generate panels of CAR+ T cells, overcoming the current need to produce panels of 
aAPC with each expressing a given TAA for a given specificity of CART. 
In summary, we report the development of an aAPC based on a CAR-specific mAb for 
the CAR-mediated propagation of CAR+ T cells with multiple specificities.  
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CHAPTER 3: Establishing anti-thymidine resistance in T cells 
INTRODUCTION 
 Certain chemotherapies used to treat cancer are able to activate the immune system. 
One of the ways chemotherapy does this is by causing the cancer to die in a way that activates 
the immune system. This is called immunogenic cell death.[76] Integrating immunogenic cell 
death with newer forms of immunotherapy, such as adoptive transfer of T cells, could 
potentially improve patient outcomes by improving the immunologic response of adoptively 
transferred T cells towards cancer.[77, 78] However, the toxicity and immunosuppressive nature 
of many of these chemotherapies prevents the concurrent use of chemotherapy with adoptive 
transfer of T cells. To utilize the immunogenicity of chemotherapy without affecting the efficacy 
of adoptively transferred T cells there are two strategies: 1) adoptively transfer T cells following 
the clearance of each dose of chemotherapy, or 2) adoptively transfer T cells genetically-
modified to resist chemotherapy-induced toxicity before the administration of multiple rounds of 
chemotherapy.  
Genetically-modifying T cells to resist toxicity from chemotherapy appears to be a 
desirable strategy, but has presented a technological challenge to the field. The depletion of T 
cells by chemotherapy is most apparent in the aftermath of allogeneic hematopoietic stem cell 
transplant (HSCT) where the conditioning chemotherapy and subsequent immunosuppressive 
chemotherapy, used to prevent graft versus host disease, prevents both anti-tumor[22] and anti-
viral[27] immunity mediated by T cells. Various groups have attempted to address this issue by 
knocking down [79] or inserting a gene which confers resistance [80] to the commonly used 
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immunosuppressive drugs tacrolimus and cyclosporine. Genetic-modification of T cells to resist 
other immunosuppressive drugs have followed including temsirolimus, [81] mycophenolate 
mofetil, [46] and immunosuppressive doses of methotrexate (MTX).[82] These modifications have 
been made using mutated human proteins (muteins) resistant to higher doses of the toxic 
chemotherapy. Unfortunately, only one mutein has been described to resist a 
chemotherapeutic agent typically used outside of the HSCT setting. That is resistance to 
temozolomide for concurrent use with T cell therapy in the treatment of brain cancer.[83] 
 Muteins resistant to chemotherapeutics targeting the most common cancers - lung, 
breast, colon, and pancreas,[84] – are lacking. In seeking a mutein for these cancers we 
considered leading candidate drugs which were non-genotoxic. Hence, the chemotherapy 
resistant T cell would receive no genotoxic insult and would not be at an increased 
susceptibility for malignant transformation. Anti-thymidylates (AThys) appeared to be the 
optimal candidate as the AThy 5-fluorouracil (5-FU) is used to treat breast, colon, and 
pancreatic cancer, [85] and lung cancer is treated with the AThy pemetrexed (Pem).[86] All AThys 
inhibit the synthesis of thymidine from uridine by blocking the activity of thymidylate synthase 
(TYMS) and/ or co-enzyme dihydrofolate reductase (DHFR) (See Figure 10A). The inhibited 
synthesis of thymidine prevents DNA synthesis, and ultimately leads to death in rapidly 
replicating cells such as activated T cells or cancer cells.[85, 86] Thus, AThy resistance (AThyR) 
conferred by a mutein TYMS and DHFR should permit resistance to 5-FU and Pem, and this 
was shown in murine bone marrow cells.[87, 88]  Here, we propose AThyR is feasible in human T 
cells using a mutein of DHFR resistant to MTX - DHFRFS, [89] in combination with a mutein of 
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TYMS. The human mutein of TYMS -  TYMSSS – has not yet been described outside of the 
bacterial system in which it was developed.[90]  
To test the ability of DHFRFS and TYMSSS to resist toxic levels of AThys, selective 
outgrowth assays were developed where AThyR+ T cells co-expressed fluorescent proteins 
that were used to track improved survival by flow cytometry. We find that combining DHFRFS 
with TYMSSS confers survival advantages to AThyR+ T cells in toxic concentrations of MTX, 5-
FU, and Pem, as expected. It is noted that TYMSSS also enhances the survival advantage of 
DHFRFS to MTX, likely through improved resistance of TYMSSS towards the anti-TYMS action 
of MTX.[86] Furthermore, we discover that a known biochemical phenomenon in which TYMS 
auto-regulates expression of TYMS[91] and DHFR auto-regulates expression of DHFR[92] is co-
opted by TYMSSS and DHFRFS. Our findings show that DHFRFS and its cis-expressed 
fluorescent protein are up-regulated by increasing doses of MTX and that TYMS cis-expressed 
fluorescence proteins are down-regulated at the same concentration of MTX. These findings 
further elucidate unknown aspects of the auto-regulatory biochemical pathway and 
demonstrate that AThyRs DHFRFS and TYMSSS can be used to increase or decrease the 
expression of cis transgene in a drug dependent manner. The ability of AThyRs to enhance 
survival in the presence of chemotherapy and inducibly change cis transgene makes these 
transgenes desirable for selecting intracellular transgenes, such as suicide genes. Thus, 
DHFRFS was used to select for the suicide gene inducible caspase 9 (iC9) [35, 93] in vitro as a 
demonstration of the utility of AThyRs in future studies involving adoptive T cell transfer. 
MATERIALS AND METHODS: 
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Cells and culture conditions: 
Cells: Peripheral blood mononuclear cells (PBMC) derived from healthy donors at the Gulf 
Coast Regional Blood Bank or MDACC Blood Bank, both in Houston, Texas, was subjected to 
density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Biosciences, 
Piscataway Township, NJ; Cat No. 17-1440-02). PBMC were washed once in CliniMACS Plus 
PBS/EDTA buffer (Miltenyi Biotec, Gladbach, Germany, Cat. No. 130-070-525) and twice in 
Dulbecco’s PBS (D-PBS) (Sigma-Aldrich, St. Louis, Missouri, Cat. No. D8537) before resting in 
complete media (CM) made of RPMI 1640 (Thermo Scientific Hyclone, Bridgewater, NJ; Cat. 
No. SH30096.01), 10% heat-inactivated fetal bovine serum (FBS -Thermo Scientific Hyclone, 
Cat. No. SH30070.03), and 2 mM GlutaMAX supplement (Life Technologies, Grand Island, NY; 
Cat. No. 35050061). Alternatively, PBMC were frozen using a prepared mixture of 50% heat-
inactivated FBS, 40% RPMI 1640, and 10% DMSO (Sigma-Aldrich, PA; Cat. No. D2650) - 
freeze media (FM) at 4 X 107 cells/ mL. The use of rested or frozen PBMC is outlined in each 
experiment. The Jurkat cell line, a human T cell acute lymphoblastic leukemia (American Type 
Culture Collection, Manassas, VA, Cat. No. TIB-152) was used and maintained in CM. The 
identity of this cell line was assured by short tandem repeat DNA fingerprinting performed by 
MDACC Cancer Center Support Grant Characterized Cell Line Core. Activating and 
propagating cells (AaPC) were used to stimulate T cells. The AaPC cell line K562 clone.4, 
expressing CD86, CD137, CD64, along with membrane bound IL-15, was modified to present 
OKT3 antibody for the polyclonal stimulation of T cells, as previously described.[94] For the 
propagation of chimeric antigen receptor (CAR)+ T cells, the AaPC CARL+ K562[95] was utilized. 
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All AaPC were rapidly thawed in a 37º C water bath and washed twice before stimulation of T 
cells.[94]  Jurkat and AaPC were tested for the presence of mycoplasma before use. Cell 
counting was accomplished in a mixture of 0.1 % Trypan Blue (Sigma-Aldrich, T8154) with the 
Cellometer K2 Image Cyotmeter (Nexcelom, Lawrence, MA). 
Chemical and biological agents: 
Stimulation via CD3 and CD28 was achieved by the addition of 30 ng/mL OKT3 antibody 
(eBioscience, San Diego, CA, Cat. No. 16-0037-85), 100 ng/ mL anti-CD28 antibody (EMD 
Millipore, Temecula, CA, Cat. No. CBL517). T cell stimulation included recombinant human IL-2 
(Proleukin, Prometheus Labs, San Diego, CA). When indicated, the following drugs were used: 
5-FU, MTX, pemetrexed, raltitrexed, G418, and AP20187. Further information regarding each 
drug is given in Table 4.   
DNA expression plasmids: 
DNA plasmids for testing AThyR transgenes were generated using the previously described 
DNA plasmid G4CAR as a backbone.[95] Commercially synthesized FLAG-DHFRFS, codon 
optimized (CoOp) DHFRFS, FLAG-TYMSSS, and CoOp TYMSSS DNA (Life Technologies, Gene 
Art), and neomycin resistance gene (NeoR) DNA product were cleaved by NheI and ApaI. 
Reporter genes mCherry with N-terminus SV40 nuclear localization sequence (RFP), inducible 
suicide gene CoOp iC9 (both produced by GeneArt), and enhanced green fluorescent protein  
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Table 4 Chemical Agents 
 
Agent Manufacturer ID No. 
5-fluorouracil APP Pharmaceuticals, Schaumburg, IL NDC 63323-117-10 
Methotrexate Hospira, Lake Forest, IL NDC 61703-350-38 
Pemetrexed Lilly, Indianapolis, IN NDC 0002-7640-01 
Raltitrexed Abcam Biochemicals, Cambridge, MA Ab142974 
G418 Invivogen, San Diego, CA Ant-gn-1 
AP20187 Clontech, Mountain View, CA 635060 
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(eGFP) DNA were digested by ApaI and KpnI. The G4CAR backbone was restriction enzyme 
digested by NheI and KpnI. The G4CAR backbone was ligated with NheI and ApaI digested 
fragments and ApaI and KpnI digested fragments in a three component ligation. Enzyme 
digestion locations of NheI, KpnI, and ApaI are shown in Figure 10B. The drug resistant 
component [DHFRFS, TYMSSS, or NeoR] was permutated with the transgenes [RFP, CoOp iC9, 
and GFP] to make the following DNA plasmids:  FLAG-DHFRFS-2A-eGFP pSBSO (DG), FLAG-
CoOp DHFRFS-2A-eGFP pSBSO (CoOp DG) FLAG-TYMSSS-2A-GFP pSBSO (TSG), FLAG-
CoOp TYMSSS-2A-GFP pSBSO (CoOp TSG), FLAG-TYMSSS-2A-RFP pSBSO (TSR), NeoR-
2A-GFP pSBSO (NRG), FLAG-DHFRFS-2A-iC9 pSBSO (DFSiC9). Codon optimization of 
DHFRFS and TYMSSS DNA was performed to avoid the mRNA transcript from being bound by 
DHFR and TYMS proteins, respectively. Known RNA binding motifs of DHFR and TYMS 
mRNA are recognized by DHFR[92] and TYMS[96], respectively. Codons of DHFRFS and TYMSSS 
were altered as much as possible while maintaining the amino acid sequence of each protein in 
order to avoid protein binding of the mRNA transcript. Previously described CD19-specific 
chimeric antigen receptor (CAR)[95] was utilized without modification.  
Myc-ffLuc-NeoR pSBSO (NRF) was constructed using the backbone of CD19-2A-Neo 
pSBSO[95] isolated after restriction digestion with NheI and SpeI. NheI and SpeI digested Myc-
firefly Luciferase (ffLuc) insert was ligated to CD19-2A-Neo backbone followed by digestion of 
the ligation product with SpeI and EcoRV. SpeI and EcoRV digested NeoR fragments were 
then ligated to the digested backbone to yield NRF. All constructs contain Sleeping Beauty 
(SB) indirect/ direct repeat (IR/DR) sites to induce genomic integration in the presence of SB  
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Table 5 Synthetic DNA/ protein sequences 
FLAG-
dmDHFR 
atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaagacgacgat
gataaggacgtcgttggttcgctaaactgcatcgtcgctgtgtcccagaacatgggcatcggcaagaacggg
gacttcccctggccaccgctcaggaatgaatccagatatttccagagaatgaccacaacctcttcagtagaa
ggtaaacagaatctggtgattatgggtaagaagacctggttctccattcctgagaagaatcgacctttaaagg
gtagaattaatttagttctcagcagagaactcaaggaacctccacaaggagctcattttctttccagaagtctag
atgatgccttaaaacttactgaacaaccagaattagcaaataaagtagacatggtctggatagttggtggcag
ttctgtttataaggaagccatgaatcacccaggccatcttaaactatttgtgacaaggatcatgcaagactttga
aagtgacacgttttttccagaaattgatttggagaaatataaacttctgccagaatacccaggtgttctctctgatg
tccaggaggagaaaggcattaagtacaaatttgaagtatatgagaagaatgat 
FLAG-CoOp 
dmDHFR 
atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaggacgatgatg
acaaagacgtcgtgggcagcctgaactgcatcgtggccgtgtcccagaacatgggcatcggcaagaacgg
cgacttcccctggccccctctgcggaacgagagccggtacttccagcggatgaccaccaccagcagcgtg
gaaggcaagcagaacctcgtgatcatgggcaagaaaacctggttcagcatccccgagaagaaccggccc
ctgaagggccggatcaacctggtgctgagcagagagctgaaagagccccctcagggcgcccacttcctga
gcagatctctggacgacgccctgaagctgaccgagcagccagagctggccaacaaggtggacatggtgtg
gatcgtgggcggcagctccgtgtacaaagaagccatgaaccaccctggccacctgaaactgttcgttaccc
gtataatgcaggatttcgagagcgataccttcttccccgagatcgacctggaaaagtacaagctgcttcccga
gtaccccggcgtgctgtccgatgtgcaggaagagaagggcatcaagtacaagttcgaggtgtacgagaag
aatgac 
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FLAG-
dmTYMS 
atgtatccgtacgacgtaccagactacgcatatccgtacgacgtaccagactacgcagacgtccctgtggcc
ggctcggagctgccgcgccggcccttgccccccgccgcacaggagcgggacgccgagccgcgtccgcc
gcacggggagctgcagtacctggggcagatccaacacatcctccgctgcggcgtcaggaaggacgaccg
ctcgagcaccggcaccctgtcggtattcggcatgcaggcgcgctacagcctgagagatgaattccctctgctg
acaaccaaacgtgtgttctggaagggtgttttggaggagttgctgtggtttatcaagggatccacaaatgctaa
agagctgtcttccaagggagtgaaaatctgggatgccaatggatcccgagactttttggacagcctgggattct
ccaccagagaagaaggggacttgggaccagtttatggcttccagtggaggcattttggggcagaatacaga
gatatggaatcagattattcaggacagggagttgaccaactgcaaagagtgattgacaccatcaaaaccaa
ccctgacgacagaagaatcatcatgtgcgcttggaatccaagagatcttcctctgatggcgctgcctccatgc
catgccctctgccagttctatgtggtgaacagtgagctgtcctgccagctgtaccagagatcgggagacatgg
gcctcggtgtgcctttcaacatcgccagctacgccctgctcacgtacatgattgcgcacatcacgggcctgaa
gccaggtgactttatacacactttgggagatgcacatatttacctgaatcacatcgagccactgaaaattcagc
ttcagcgagaacccagacctttcccaaagctcaggattcttcgaaaagttgagaaaattgatgacttcaaagc
tgaagactttcagattgaagggtacaatccgcatccaactattaaaatggaaatggctgtt 
FLAG-CoOp-
dmTYMS 
atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaggacgatgatg
acaaagacgtccccgtggccggcagcgagctgcctagaaggcctctgcctcctgccgctcaggaaaggga
cgccgaacctagacctcctcacggcgagctgcagtacctgggccagatccagcacatcctgagatgcggc
gtgcggaaggacgacagaagcagcacaggcaccctgagcgtgttcggaatgcaggccagatacagcct
gcgggacgagttccctctgctgaccaccaagcgggtgttctggaagggcgtgctggaagaactgctgtggtt
catcaagggcagcaccaacgccaaagagctgagcagcaagggcgtgaagatctgggacgccaacggc
agcagagacttcctggacagcctgggcttcagcaccagagaggaaggcgatctgggtcccgtgtacgggtt
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tcaatggcggcacttcggcgccgagtatcgggacatggagagcgactacagcggccagggcgtggacca
gctgcagagagtgatcgacaccatcaagaccaaccccgacgaccggcggatcatcatgtgcgcctggaa
ccccagagatctgcccctgatggccctgcctccatgtcacgccctgtgccagttctacgtcgtgaactccgagc
tgagctgccagctgtaccagcggagcggcgatatgggactgggcgtgcccttcaatatcgccagctacgcc
ctgctgacctacatgatcgcccacatcaccggcctgaagcccggcgactttatccacaccctgggcgacgcc
catatctacctgaaccacatcgagcccctgaagattcagctgcagcgcgagcccagacccttcccaaagct
gcggatcctgcggaaggtggaaaagatcgacgacttcaaggccgaggacttccagatcgagggctacaa
cccccaccccacaatcaagatggaaatggccgtg 
eGFP forward 5` cccgggcccggcgccatgccacctcctcgcctcctcttc 3` 
eGFP reverse 5` ggtacccttgtacagctcgtccatgccgagagtgatcccggcggcggtcac 3`  
NeoR forward 5’ gctagcacatgtgccaccatgattgaacaagatggattgcacgcaggttctccggccgcttgg 3`  
Neo R reverse 5’ 
aagcttccgcggccctctccgctaccgaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaat
c 3` 
NLS MAPKKKRKVGIHRGVP 
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transposase. Each transgene is promoted using elongation factor 1 alpha (EF1-α) promoter. 
Cartoon representations of frequently used constructs can be seen in Figure 10 B and Figure 
17A. Select DNA and protein sequences can be found in Table 5. 
Genetic Modification and Propagation of Cells: 
The Amaxa Nucleofector® II (Lonza, Allendale, NJ) was used to electroporate both 
Jurkat and human PBMC. Electroporation of Jurkat cells utilized a modified buffer[97] containing 
5 mM KCl, 15 mM MgCl2, 120 mM Na2HPO4/NaH2PO4, pH 7.2, and 50 mM DMSO, where 106 
Jurkat cells per cuvette were electroporated using program T-14 before immediate transfer to 
CM. The addition of drug occurred 48 hours after electroporation and cell culture remained 
undisturbed until sampling for gene expression on days 10-12 post electroporation. Human 
PBMC electroporation followed a previously described protocol.[95] Briefly, 1 to 2 X 107 thawed 
PBMC per cuvette were electroporated in Amaxa T cell Nucleofector solution (Lonza 
Biosciences; Cat No. VPA-1002) using program U14. On the following day, PBMC were 
stimulated in fresh CM with AaPC at a ratio of 1: 1 including 50 IU/ mL IL-2, unless otherwise 
noted. The cellular co-culture concentration of 106 cells/ mL was maintained at each 
stimulation, and PBMC derived T cells were re-stimulated every 7 days using the same 
concentrations. IL-2 was added when media was changed between stimulations. Drug 
treatment initiated 48 hours after co-culture began and continued until day 14. Drug was only 
added with fresh CM. 
Western blot: 
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106 T cells were centrifuged from culture, supernatant aspirated, and the pellet rapidly 
frozen in liquid nitrogen. Whole-cell extracts were harvested using 50 mM Tris, 150 mM NaCl, 1 
mM EDTA, 1% NP-40, 0.5% deoxycholate, 1mM phenylmethylsulfonyl fluoride, 150 mM p-
nitrophenyl phosphate and 0.3 µM Aprotinin, pH 7.4. Proteins were separated by SDS-PAGE in 
reducing conditions and analyzed using specific primary antibodies indicated in Table 
6.  Detection was performed using an enhanced chemiluminescence detection system. 
Flow cytometry:  
Cultured cells were resuspended, and washed once in FACS staining solution.[95] If 
transgene expression alone was sought, the specimen was then analyzed on a flow cytometer. 
The BD LSRFortessa (BD Biosciences) was used to analyze RFP expression; otherwise, BD 
FACSCalibur (BD Biosciences) was used. Surface antibody staining was performed in FACS 
staining solution with fluorochrome-conjugated antibodies at 4º C for at least 30 minutes. 
Antibody targets, concentrations, and manufacturers are listed in Table 7. Analysis of flow 
cytometry data utilized FlowJo v 10.0.5 (Tree Star Inc., Ashland, OR).  
Luciferase assay: 
Cultured T cells were tested for the persistence of ffLuc transgene by the cleavage of D-
luciferin (Perkin Elmer, Waltham, MA, Cat. No. 122796). Resuspended cells were plated and 
washed once in D-PBS before testing in a D-PBS solution of D-luciferin at 0.14 mg/ mL. After 
incubation at 37 º C for 10 min, the plate was analyzed on a TopCount NXT Luminescence 
Counter (Perkin Elmer).  
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Table 6 Western Blot Antibodies  
Antibody Manufacturer Cat. No. Dilution 
Actin Sigma A2228 1:10000 
Hsp-70 Santa Cruz Biotechnology, Dallas, TX SC-24 1:5000 
DHFR Santa Cruz Biotechnology SC-377091 1: 1000 
TYMS Millipore MAB4130 1: 1000 
Myc Tag CST 2276S 1: 1000 
DYKDDDDK Tag Pierce MA1-91878 1: 1000 
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Table 7 Flow Cytometry Antibodies  
Antibody Manufacturer Cat. No.  Dilution 
CD3-APC BD Pharmingen 340661 1:33 
CD3-PerCP-Cy5.5 BD Pharmingen 340949 1:33 
CD4 FITC BD Pharmingen 340133 1:33 
CD4 -PE BD Pharmingen 347327 1:33 
CD4-PerCP-Cy5.5 BD Pharmingen 341645 1:33 
CD8-APC BD Pharmingen 340659 1:33 
Annexin V-PE BD Pharmingen 556422 1:20 
7-AAD BD Pharmingen 559925 1:20 
Propidium Iodide BD Pharmingen 556463  
Human Fc-PE Invitrogen H10104 1:40 
Myc- AF488 MBL M047-A48 1:33 
FLAG-AF647 Cell Signaling 3916S 1:33 
 
 
 
 
 
64 
 
Chromium Release Assay: 
Antigen specific cytotoxicity was assessed by chromium release assay (CRA). This 
assay was previously described.[95] Briefly, antigen positive CD19+ EL-4 were compared to 
antigen negative CD19neg EL-4 after each cell line was loaded with 51Cr for 3 hours and 
subsequently incubated with CD19-specific CAR+ T cells at a 1 target : 5 effector cell ratio for 6 
hours.  Release of 51Cr from cell lysis was assessed by the TopCount NXT scintillation counter.  
Statistical Analysis: 
Statistical analysis and graphical representation of data was achieved using Prism v6.0 
(Graph Pad Software Inc., La Jolla, Ca). Experiments of more than one variable were analyzed 
by multivariate analysis: Two-Way ANOVA was used when appropriate with Sidak’s multiple 
comparison test, One-Way ANOVA was used when appropriate with Tukey’s or Dunnett’s 
multiple comparison tests as applicable, non-Gaussian distributions were assessed by the 
Kruskall-Wallis test followed by Dunn’s multiple comparison test. Single variable tests 
(experimental vs. control) were made using the Mann-Whitney test. Statistical significance was 
designated as α < 0.05. 
RESULTS:  
Testing AThyR transgene selection in Jurkats.   
Jonnalagadda et. al recently developed DHFRFS+ T cells resistant to MTX with in vitro 
and in vivo applications.[46, 82] The studies focused on demonstrating that DHFRFS+ T cells 
continue to survive and function in a moderate dose of MTX used post-HSCT. We continued 
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using DHFRFS to determine whether T cells can be genetically-modified to resist toxic doses of 
AThys used in the initial treatment of malignancy. For this purpose, a combination of mutein 
human TYMS with DHFRFS was sought. 5-FU resistant TYMS muteins previously identified 
within a bacterial culture system[90] were tested in human cells (not shown) and TYMSSS was 
chosen for further study.  
To test the enhanced survival of each AThyR, constructs individually expressing 
DHFRFS, TYMSSS, and NeoR were ligated into the same backbone containing Sleeping Beauty 
(SB) transposable elements upstream of eGFP (Figure 10B). eGFP was used to track the 
predominance of surviving genetically-modified T cells. Jurkat cells were co-electroporated with 
each construct and SB11 transposase [57] which mediated genomic integration of each 
construct. Cytotoxic drugs were added two days after electroporation. Jurkat were assessed for 
eGFP expression in viable cells by propidium iodide (PI) exclusion on day 10-12 (Figure 10C). 
Increased percentage expression of eGFP was sought as a measure for transgene selection in 
the presence of drug. Overall survival and mean fluorescence intensity (MFI) of eGFP are also 
given in Figure 11AI and AII, respectively.  Overall, we demonstrate that DHFRFS has much 
better selection than the traditional drug-resistance transgene NeoR. We also demonstrate that 
TYMSSS has no independent capacity to enhance Jurkat survival.  
More specifically, we found that DHFRFS confers resistance to MTX at concentrations 
range of 0.01-0.5 µM, and codon optimization of DHFRFS enhanced the drug resistance range 
of CoOp DHFRFS to 0.01-1 µM (Figure 10C). Codon optimization removed potential 
endogenous DHFR binding to the DHFRFS mRNA as well as possible micro RNA binding 
66 
 
domains.[92] Notably, gating on eGFP+ cells demonstrated that DHFRFS constructs lead to a 
MTX dependent increase in eGFP MFI. Hence, eGFP expression within a single cell increased 
based on the addition of MTX. This finding occurred independent of mRNA regulation until 5 
µM MTX where endogenous codon DHFRFS expression significantly decreased compared to 
CoOp DHFRFS (p< 0.0001) (Figure 11A-II). Drug inducible transgene expression is a rare 
phenomenon. This phenomenon, although rare, is not novel and the capacity of DHFR to 
increase cis-expressed eGFP in an MTX dependent manner was previously described for 
native DHFR. However, this was attributed to MTX binding DHFR, DHFR releasing DHFR 
mRNA, and free DHFR mRNA leading to increased translation of DHFR protein.[98] Here we 
note that the phenomenon also occurs with MTX resistant DHFRFS, and with DHFRFS occurs 
independent of mRNA regulation from 0.01 – 1 µM MTX. Hence, we postulate the regulation of 
DHFR expression occurs partially through an mRNA independent mechanism, which has not 
been described to our knowledge. We further explore this mechanism in later sections 
As noted, there was no drug selective advantage for TYMSSS expressing Jurkat when 
tested with 5-FU (Figure 10C). Native codon TYMSSS had no expression advantage over No 
DNA Jurkat at any concentration of 5-FU. Further analysis of eGFP+ cells for eGFP MFI 
revealed that TYMSSS expressed at a lower eGFP MFI compared to CoOp TYMSSS (Figure 
11A). We conclude that lower expression of TYMSSS due to mRNA based suppression 
contributed to the lack of TYMSSS survival advantage. When mRNA regulatory mechanisms are 
ablated by codon optimization, TYMSSS has a significant  
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Figure 10 
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Figure 10 Testing enhanced survival by selection of anti-thymidylate (AThy) resistance 
(AThyR) transgenes in Jurkats. (A) The synthesis of thymidine is crucial to DNA replication 
and cell survival. It has long been a target of AThy chemotherapeutic agents like methotrexate 
(MTX), Pemetrexed (Pem), and 5-fluorouracil (5-FU) in many common forms of cancer.  (B) 
Putative AThyR transgenes resistant to AThy toxicity were designed in order to confer 
resistance to T cells that might be used in a combination therapeutic with AThy chemotherapy. 
AThyRs were co-expressed with a fluorescent protein to indicate that surviving cells contained 
the transgene. These transgene utilized the Sleeping Beauty transposon/ transposase system 
to induce stable transgene expression in Jurkat. Human muteins DHFRFS - resistant to MTX 
(left), human mutein TYMSSS - resistant to 5-FU (center), and the gold-standard Neomycin 
resistance gene (NeoR) drug resistance gene - resistance to G418 (right) were used in this 
study. Codon optimized (CoOp) versions of DHFRFS & TYMSSS replaced native codon DHFRFS 
& TYMSSS to test whether known post-transcriptional regulatory mechanisms were affecting 
AThyR selection or survival. (C- left) DHFRFS-2A-GFP (DG), CoOp DG, and no DNA, were 
electroporated into Jurkat and subjected to MTX after 2 days. (C- center) TYMSSS-2A-GFP 
(TSG), CoOp TSG, and No DNA electroporated Jurkat were treated on day 2 with 5-FU. (C- 
right) NeoR-GFP and No DNA electroporated Jurkat were treated on day 2 with G418. For 
each experiment in C the percentage of eGFP+ viable Jurkat is given after testing on day 8-10 
after the addition of drug. (D) MTX and Pem are known to inhibit native DHFR and TYMS, DG 
and TYMSSS-2A-RFP (TSR) were co-electroporated into Jurkat to determine whether 
combination DHFRFS & TYMSSS confer enhanced survival to MTX (left) or Pem (right). (E) 
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Following 2 weeks of selection in 1 µM MTX, [DHFRFS & TYMSSS]+ Jurkat displayed a uniform 
and repeatable pattern of correlated expression. Shown here, four separate [DHFRFS & 
TYMSSS]+ Jurkat experiments are overlaid in different colors. Experiments were independently 
repeated at least twice with 4-6 replicates. * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p 
<0.0001.  ; Dihydrofolate (DHF); DHF reductase (DHFR); deoxyuridine monophosphate 
(dUMP); deoxythymidine monophosphate (dTMP); 5, 10 – methylenetetrahydrofolate (5,10 
CH2THF); nicotinamide adenine dinucleotide phosphate (NADP). 
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Figure 11 
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Figure 11 Contributory findings in the testing of individual and combined AThyR 
selection for Jurkats. Jurkat were electroporated with AThyR or NeoR drug resistance 
transgenes and treated from day 2 until days 10-12 with appropriate drug. The enhancement in 
survival of Jurkat expressing transgene is noted in Figure 1. Here the enhanced survival, as 
determined by PI exclusion (I), and alterations in the mean fluorescent intensity (MFI) of eGFP 
(II), are given for DHFRFS (left), TYMSSS (right), and NeoR (center). (B) Raltitrexed (Ral) is an 
anti-folate AThy known to primarily inhibit native TYMS. DHFRFS & TYMSSS were co-
electroporated into Jurkat treated with Ral to determine whether this transgene combination 
enhanced survival. (C) Observations suggested that cells expressing DHFRFS & TYMSSS as 
independent plasmids have correlated expression of each plasmid. This could have 
implications in the co-regulation of DHFRFS with TYMSSS. Hence, the MFI of eGFP and RFP 
were correlated for treatments with multiple concentrations of MTX, Pem, and Ral. The linear 
regression data is included in the figure. Each experiment was independently repeated at least 
twice with 4-6 replicates. * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001. 
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expression advantage over mock electroporated Jurkat, and a weak survival advantage in 5 µM 
5-FU. The lack of significantly enhanced survival is likely due to an alternative mechanism of 5-
FU contributing to toxicity, which is likely the known inhibition of mRNA and rRNA synthesis by 
5-FU.[85, 99]   
 NeoR is one of the first drug resistance transgenes utilized in mammalian cells.[45] Here, 
NeoR was used to select for enhanced survival of Jurkat in the presence of G418. This was 
intended to serve as a standard to gauge the utility of DHFRFS and TYMSSS. Electroporation of 
NeoR into Jurkat improved survival in the presence of G418, as expected, at 0.72-1.1 mM 
G418 (Figure 10C). The survival advantage of NeoR over No DNA was not significant due to 
variability (Figure 11A), but a G418 dependent increase in GFP MFI was noted. The GFP MFI 
significantly increased above No DNA Jurkat at 1.4 mM G418 (Figure 11A-II). These results 
reinforce that DHFRFS and NeoR are capable of providing dose-dependent transgene selection 
advantage in surviving Jurkat. However, only DHFRFS conferred reliable survival advantages to 
Jurkat in this experiment (Figure 11A-II).  
The next experiment combined DHFRFS and TYMSSS by co-electroporating each 
plasmid into Jurkat. The capacity of the combined transgenes to resist commonly used anti-
folate AThys: MTX, Pem, and Raltitrexed (Ral), were tested. As before, drug was added on day 
2 and cells were tested on day 10-12. There was clear selection for [DHFRFS & TYMSSS] 
expressing Jurkat in 0.1 - 1 µM MTX when compared to similarly treated No DNA or untreated 
[DHFRFS & TYMSSS]+ Jurkat (Figure 10D). It should be noted that endogenous codon DHFRFS 
was used in these experiments and the resistance to MTX was enhanced from 0.5 (Figure 
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10C) to 1 µM MTX (Figure 10D) by the addition of TYMSSS with no other changes to the 
experimental conditions. Selection was also noted for 50-100 µM Pem (Figure 10D). Moderate 
selection was also noted with 10 µM Ral when compared to untreated [DHFRFS & TYMSSS]+ 
Jurkat (Figure 11B). Ral primarily targets TYMS, whereas MTX and Pem target both DHFR 
and TYMS, [86] hence the improved selection for MTX and Pem over Ral in [DHFRFS & 
TYMSSS]+ Jurkat. After 2 weeks within 1 µM MTX, surviving [DHFRFS & TYMSSS]+ Jurkat were 
refreshed in untreated media and grown for 3-5 weeks. Subsequently, the stability of transgene 
expression of [DHFRFS & TYMSSS]+ Jurkat was tested by flow cytometry with the co-expression 
of eGFP representing DHFRFS expression and RFP representing TYMSSS expression as seen 
in Figure 10E. Each color represents a separate experiment and is overlaid to represent the 
trend that DHFRFS and TYMSSS co-express in a correlated fashion. In fact, analysis of GFP MFI 
representing DHFRFS expression and RFP MFIs representing TYMSSS expression over multiple 
anti-folate drugs, at multiple concentrations demonstrated that DHFRFS & TYMSSS co-express 
with a strong Pearson’s correlation (R2 = 0.9) (Figure 11C). This finding suggests that 
expression of DHFRFS is somehow regulated by the expression of TYMSSS, or vice versa. 
These findings begin to suggest a more complex mechanism for the expression of DHFR and 
TYMS that is inter-related. 
Selective propagation of primary human T cells resistant to MTX and/ or 5-FU.  
As demonstrated, TYMSSS enhances the ability of Jurkat expressing DHFRFS to survive 
in the presence of MTX and Pem, which both target endogenous DHFR and TYMS to prevent 
thymidine synthesis. Given the more robust survival to toxic MTX concentrations conferred by 
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DHFRFS and TYMSSS, we pursued experiments with MTX as a proof-of-concept to demonstrate 
anti-folate and AThy resistance. Based on the findings above, it is anticipated improved survival 
in the presence of MTX will translate into improved survival in the presence of Pem. TYMSSS 
with DHFRFS were tested in human cells by electroporation into human PBMC.  The day 
following electroporation, cells were stimulated with an OKT3-loaded AaPC capable of 
polyclonal T cell propagation.[94] The propagation schematic is shown in Figure 12A. Two days 
after AaPC stimulation, the co-cultures received 0.1 µM MTX, 5 µM 5-FU, or 1.4 mM G418 until 
day 14, as designated in Figure 12. The co-cultures were re-stimulated with AaPC at a 1: 1 
ratio and given 50 IU / mL IL-2 every 7 days from day 1 to 35. Phenotypic changes in 
transgene expression were tracked during drug administration for the first 14 days and for the 
21 days after drug administration had ended. The weekly changes in transgene expression can 
be noted in Figure 12B-I, C-I, D-I.  
Initial testing of DHFRFS, TYMSSS, and NeoR co-expressed with fluorescent proteins 
demonstrated rapid and persistent selection to nearly complete selection for expression of 
DHFRFS with MTX and NeoR with G418 (Figure 12B-I).  Survival and propagation of AThyR+ T 
cells (TAThyR) compared to No DNA T cells on day 21 showed that the presence of AThyR or 
NeoR transgene was crucial to T cell survival and growth (Figure 13A). On day 35, total 
inferred cell count for T cells expressing AThyR and NeoR transgenes were compared to 
untreated No DNA T cells, and NeoR+ T cells were the only T cells with significantly inferior 
growth at Day35 (Figure 13B-I). In opposition to experiments in Jurkat, TYMSSS demonstrated 
selection within the population of surviving T cells on Day 21 in the presence of   
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Figure 12 
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Figure 12 Selective propagation of primary human T cells resistant to MTX and 5-FU. (A) 
Testing for selection of AThyR transgenes in primary T cells was accomplished by co-
electroporation of AThyR transposon and SB transposase DNA plasmids into PBMC. The 
following day electroporated PBMC were stimulated with OKT3-loaded activating and 
propagating cells (AaPC) at a 1:1 ratio and 50 IU/ mL IL-2. Drug was added on day 2 and 
maintained at the same concentration until day 14. Every 7 days, fresh AaPC and IL-2 were 
added at the same concentration until day 35. (B-I) After electroporation, T cells were tracked 
for expression of AThyRs DHFRFS - DG, TYMSSS - TG, both [DG & TSR], and NeoR -NRG in 
the presence (day 2-14) then absence (day 14-35) of appropriate selection drug. (C-I) Myc-
ffLuc-2A-NeoR (NRF) was combined with each AThyR transgene; [DG & NRF], [TSG & NRF], 
and [DG & TSR & NRF] in order to improve selection for AThyRs selected by 5-FU.  Selection 
occurred under the same condition with the exception that 100 IU IL-2/ mL was added to 
promote outgrowth of cells treated with G418. (D-I) To elucidate the influence of 5-FU and 
TYMSSS on the selection of DHFRFS, RFP or TYMSSS-RFP (TSR) were co-electroporated into T 
cells with DHFRFS. There were no experimental differences from the outline noted in (A). The 
percentage of T cells expressing co-receptor CD4 is shown to the right of each corresponding 
experiment on Day 35 for B-II, C-II, and D-II. All experiments contain 5-6 biological replicates 
with each experiment independently repeated two times. * = p < 0.05; ** = p <0.01; *** = p 
<0.001; **** = p <0.0001. 
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5-FU. However, the selected TYMSSS expressing T cells did not persist to Day 35, and the lack 
of persistence was also noted when [DHFRFS & TYMSSS] were selected using MTX and 5-FU. 
One possible explanation for this is that thymidine synthesis is restored by TYMSSS and 
thymidine transporters then make thymine available to un-transformed cells. This is likely 
mediated by an equilibrative nucleoside transporter as the same transporter that permits 5-FU 
entry also mediates equilibrative transport of thymine.[100] As TYMSSS restores thymidine 
synthesis in the presence of methotrexate, DHFRFS is no longer able to select for T cells 
expressing DHFRFS & TYMSSS as noted in Figure 12B – I. 
In order to achieve complete selection of TYMSSS for possible use in combination 
therapies, NeoR was co-electroporated into primary T cells with DHFRFS, TYMSSS, and 
[DHFRFS & TYMSSS]. The only change made to the propagation method was the addition of 
100 IU/ mL IL-2 rather than 50 IU/ mL from days 14-35 to supplement the poor outgrowth 
already noted in G418 selected T cells. The higher doses of IL-2 were insufficient to rescue 
poor outgrowth when G418 and 5-FU were combined for T cell selection (Figure 13B-II). With 
the co-transfection of NeoR into DHFRFS and/or TYMSSS expressing T cells, nearly 100% 
transgenes selection was observed with the same transgene selection kinetics among all 
groups (Figure 12C-I).  
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Figure 13 
 
Figure 13 Propagation characteristics of AThyR+ T cells in the presence or absence of 
MTX, 5-FU, and/ or G418. (A) AThyR and NeoR electroporated primary T cells are compared 
on Day 21 to mock-electroporated T cells treated with the same conditions. The continued 
propagation of the same experiment is shown on day 35 (B-I). This can be compared to day 35 
changes in outgrowth potential for primary T cells when NeoR is combined with DHFRFS and/or 
TYMSSS (B-II). (B-III) Subsequently, the influence of 5-FU on preserving outgrowth potential for 
primary T cells on day 35 was tested. Each experiment was independently repeated at least 
twice with 5-6 replicates. * = p < 0.05, ** = p <0.01. 
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Figure 14 
 
 
 
 
 
 
 
80 
 
Figure 14 MTX alters expression of cis-transgenes co-expressed with AThyRs (A) Jurkat 
transformed with DHFRFS - DG, CoOp DHFRFS - CoOp DG, and [DG & TYMSSS - TSR] were 
cultured with 1 µM MTX for 2 weeks before culturing without MTX for 3-5 weeks. The stable 
fluorescent protein expression, in the absence of MTX, is depicted by MFI. (B-I) AThyR+ Jurkat 
were treated for 72 hours with 0.5 µM MTX or no treatment. The ∆ MFI difference (∆ = eGFP 
MFI MTX treated – eGFP MFI untreated) is depicted. (B-II) A representative histogram 
demonstrates the MTX induced change in eGFP MFI for DHFRFS and CoOp DHFRFS in Jurkat. 
In primary T cells from the experiment noted by Figure 2C, day 35 T cells were stimulated with 
anti-CD3, anti-CD28 antibodies, and 50 IU/ mL IL-2 in the absence of MTX. The fluorescent 
protein MFI is shown in (C), and (D-I) depicts the ∆ MFI after 72 hours of treatment with 0.5 µM 
MTX in comparison to no treatment.  (D-II) A representative histogram demonstrates the 
observed shift in eGFP fluorescence for DHFRFS+ T cells in the presence or absence of MTX. 
Kruskall-Wallis test was used to determine significant differences. (E) Further experiments in 
primary T cells assessed the influence of TYMSSS on blunting the MTX-induced increase in 
eGFP co-expressed with DHFRFS. This was performed 72 hours after treatment on day 35 with 
anti-CD3, anti-CD28 antibodies, 50 IU/ mL IL-2, and varying concentrations of MTX. The MTX 
induced change in eGFP MFI for DHFRFS is shown in (I), while the influence of MTX on RFP 
and RFP co-expressed with TYMSSS (TSR) is shown in (II). Jurkat and primary T cell 
experiments included 6 replicates independently repeated twice; * = p < 0.05, ** = p <0.01, *** 
= p <0.001, **** = p <0.0001. 
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Figure 15 
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Figure 15 Flow plots of transgene expression for AThyR experiments on day 35. Flow 
plots of CD4 and GFP expression depict day 35 of a series of experiments designed to 
characterize the selection and maintenance of transgene expression in donor T cells. T cells 
grown for 35 days with days 2-14 in the presence of cytotoxic drugs MTX, 5-FU, G418, or a 
combination, as noted above the flow plot, are shown; (A) corresponds to the experiment 
described for Figure 2B,  (B)  corresponds to the experiment described for Figure 2C, (C) 
corresponds to the experiment described for Figure 2D. (D) The presence of ffLuc-2A-NeoR – 
NRF - on day 35 for experiment noted in (B) is demonstrated using D-luciferin to induce T cell 
chemiluminescence.  Each experiment was independently repeated at least twice with 6 
replicates. Representative flow plots are depicted. * = p < 0.05, ** = p <0.01, *** = p <0.001. 
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The influence of TYMSSS on DHFRFS selection in T cells subjected to MTX was tested. 
Plasmids expressing DHFRFS were co-electroporated into T cells along with either TYMSSS co-
expressing RFP or a vector expressing RFP alone. This experiment followed the same strategy 
as described for Figure 12B. Due to technical limitations, the total amount of DHFRFS 
expressing plasmid DNA electroporated into the same number of T cells was decreased. 
Consequently, fewer T cells initially expressed DHFRFS at the beginning of the experiment and 
DHFRFS was incompletely selected by the addition of MTX within a 14 day time period (Figure 
12D - I). The progressive loss of DHFRFS after day 14 is reminiscent of TYMSSS expression in 
Figure 12B – I. This demonstrates that AThyR transgenes must select for nearly the entire T 
cell population to maintain stable expression within the population. With regards to the 
influence of TYMSSS on the selection of DHFRFS, it appears that TYMSSS blunts DHFRFS 
selection in T cells as selection of [DHFRFS & RFP] expressing T cells was more robust than 
selection of [DHFRFS & TYMSSS] expressing T cells. This is attributed to the restoration of 
thymidine synthesis in the presence of TYMSSS (Figure 12D - I). The presence of 5-FU 
prevents selection of DHFRFS with or without TYMSSS, and this is attributed to the TYMSSS 
independent inhibition of mRNA and rRNA synthesis previously mentioned.[85, 99]  
It was also noted that transgenic selection tended to increase the population of CD4+ T 
cells by day 35 in all T cell experiments, which was not seen with un-modified T cell cultures. 
This was noted in any experiment involving one or more transgenes selected in the presence of 
cytotoxic drug (Figure 12B – II, 12C – II, 12D – II, respective flow plots seen in Supplemental 
Figure 15A, 15B, and 15C). The experiment in Figure 12D - II demonstrates that it is not 
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caused by cytotoxic drug, rather, the presence of transgene in combinations with cytotoxic drug 
leads to CD4+ T cell predominance by day 35. The selection towards CD4+ T cell 
predominance was not noted 7 days after initial drug selection for AThyR+ T cells (Figure 
13C), which is consistent with previously published findings using DHFRFS T cells.[82] The 
longer period of follow-up than prior experiments demonstrated a previously unknown 
phenomenon that CD8+ T cells are unable to persist for long periods of time following cytotoxic 
insult, or are selectively outgrown by CD4+ T cells. The mechanism underlying this 
phenomenon is not known. 
MTX increases cis-transgene expression in DHFRFS+ T cells 
MTX mediated changes in transgene expression could be used in animal models and 
humans as a tool for in vivo control of transgene expression. To our knowledge, a system 
utilizing clinically available drugs to mediate transgene expression either up or down in T cells 
has not been described. Hence, we targeted the known drug-inducible regulation of DHFR by 
MTX [98] for use in T cells. The MTX-inducible expression of transgenes co-expressed with 
mutein DHFRFS is unknown, and the point mutations may have ablated the MTX-inducible 
expression mechanism. In order to examine whether this phenomenon persists,  DHFRFS, 
CoOp DHFRFS, and [DHFRFS & TYMSSS] expressed in Jurkat were selected in 1 µM MTX for 2 
weeks and rested for 3-5 weeks before testing MTX mediated regulation of DHFRFS 
expression.  By this time, expression of eGFP in each cell was uniformly positive, but the 
expression level of eGFP, as signified by the MFI, varied based on the choice of AThyR co-
expressing eGFP (Figure 14A). DHFRFS, CoOp DHFRFS, and [DHFRFS & TYMSSS] expressing 
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Jurkat were subjected to 72 hours incubation in 0.5 µM MTX, a concentration all DHFRFS+ cells 
were expected to survive. Cells treated with MTX showed a significant increase in eGFP MFI 
for both DHFRFS and CoOp DHFRFS in comparison to the same cells untreated (Figure 14B-I 
and histogram Figure 14B-II). The increase in eGFP MFI was equivalent between DHFRFS and 
CoOp DHFRFS after 72 hours, suggesting that the up-regulation of eGFP is independent of the 
mRNA binding mechanism previously thought to mediate this phenomenon.[92, 101] An 
alternative regulatory mechanism based on the presence of thymidine is suggested here. As 
previously shown, TYMSSS restores the synthesis of thymidine in MTX treated Jurkat. In this 
experiment, the co-expression of TYMSSS with DHFRFS in Jurkat blunts the MTX induced 
increase in eGFP MFI (Figure 12B-I). Thus, DHFRFS maintains MTX-inducible expression of 
cis-transgenes which is dependent on MTX mediated inhibition of TYMS.      
This phenomenon was next tested in primary T cells. In order to uniformly select each 
AThyR in primary T cells, AThyRs were co-electroporated with a NeoR selection plasmid as 
described for Figure 12C-II. By day 35, all AThyR+ T cell groups uniformly expressed 
transgene, and the fluorescent protein MFI from each T cell group may be noted in Figure 14C. 
On day 35, primary T cells were subjected to 72 hours of 0.5 µM MTX following anti-CD3/ 
CD28 mediated stimulation. The T cells were tested on day 38, and MTX significantly 
increased eGFP MFI for DHFRFS+ cells, as expected. However, upon testing TYMSSS in primary 
T cells, it was found that MTX mediates a decrease in eGFP MFI for TYMSSS expressing T 
cells (Figure 14D-I). The decrease in eGFP expression demonstrated for TYMSSS+ T cells in 
the presence of MTX was consistent across donors and ablated by the restoration of 
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dihydrofolate reduction to tetrahydrofolate by DHFRFS. Prior reports demonstrated that 
dihydrofolate reversed or prevented TYMS binding to TYMS mRNA.[91] Thus, MTX mediated 
decreases in dihydrofolate likely re-establishes TYMS binding to TYMSSS mRNA preventing 
expression of eGFP. This phenomenon has not been reported to our knowledge and may be of 
scientific and clinical value. Furthermore, TYMSSS continued to blunt the MTX-mediated 
increase in eGFP MFI co-expressed with DHFRFS, as was previously noted in Jurkat. The 
histogram in Figure 14D-II depicts the MTX-mediated changes in cis-expressed eGFP for 
DHFRFS and [DHFRFS & TYMSSS] expressing T cells. 
T cells from the experiment shown in Figure 12D were also subjected to varying 
concentrations of MTX. On day 35, T cells received anti-CD3/ CD28 stimulation and were 
subjected to a range of MTX from 0 to 1 µM for 72 hours. On day 35, no T cell group 
significantly expressed DHFRFS, as indicated by co-expressed eGFP, above background 
(Figure 12D – I). However, DHFRFS+ T cells selected with MTX alone persisted enough to 
significantly improve survival when MTX was re-introduced at concentrations up to 0.5 µM MTX 
(Figure 16B). Flow plots in Figure 16A demonstrate MTX-dependent increases in transgene 
expression and improved survival for transgene expressing T cells for one donor. It should be 
noted that the addition of TYMSSS in [DHFRFS+ & TYMSSS]+ T cells permitted the survival of 
transgene negative cells at 1 µM MTX, which was not seen in TYMSSS neg T cells subjected to 
MTX (Figure 16C). Presumably, TYMSSS re-established thymidine synthesis in the presence of 
MTX and equilibrative thymidine transport permitted transgene negative T cells to restore DNA 
synthesis and survive. MTX-inducible up-  
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Figure 16 
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Figure 16 AThyR rescue of AThyR+ and AThyRneg T cells following 72 hours treatment in 
MTX. T cells from the experiment described for Figure 12D were stimulated on day 35 with 
anti-CD3, anti-CD28, and IL-2 along with varying doses of MTX [0, 0.1, 0.5, 1 µM] for 72 hours. 
The gating strategy and representative flow plots are shown in (A). While enhanced viability of 
AThyR+ T cell cultures is shown in (B). In (C), Viable, CD3+, GFPneg, RFPneg T cells (AThyRneg) 
were assessed for survival. Each experiment was independently repeated at least twice with 6 
biologic replicates total. Representative flow plots from one are depicted; ns = no significance; * 
= p < 0.05, ** = p <0.01, *** = p <0.001; **** = p<0.0001. 
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regulation of eGFP co-expressed by DHFRFS and blunting of this eGFP up-regulation by 
TYMSSS was again observed (Figure 14E – I). Of note, the RFP co-electroporated with 
DHFRFS up-regulated in increasing concentrations of MTX, whereas RFP co-expressed by 
TYMSSS did not (Figure 14E – II). This further indicates that it is the absence of thymidine 
which leads to increases in co-expressed transgene. 
AThyR permits independent selection for transgenes of interest.  
AThyRs are human proteins and therefore have lower immunogenicity in humans than 
NeoR or similar drug resistance transgenes, typically originating from bacteria.[45] Thus, using 
AThyRs to select transgenes of interest is desirable due to lower immunogenicity, and ease of 
use in vitro. As a proof-of-principle, the suicide gene inducible caspase 9 (iC9) was selected by 
co-expressing iC9 with DHFRFS in a construct designated DFSiC9 (Figure 17A). Current 
methods to select iC9 utilize surface-expressed antigen and isolation by magnetic beads.[35] 
However, this method of selection is more labor intensive than adding drug and does not add 
the functionality of AThy resistance. The DFSiC9 plasmid significantly selected for survival in T 
cells after 7 days of AaPC based stimulation including days 2 - 7 days in 0.1 µM MTX (Figure 
17B). Next, DFSiC9 was co-electroporated with CAR to express in T cells. The CAR was 
specifically selected by a CAR exodomain binding ligand (CARL)+ K562 AaPC,[95] while DFSiC9 
was selected using 0.1 µM MTX. After days 2 - 14 in 0.1 µM MTX, CAR+ DFSiC9+ T cells were 
rested from MTX or selected for another 7 days in 0.1 µM MTX. T cells selected in 0.1 µM MTX 
from day 2 - 21 are shown in Figure 17C compared to mock-electroporated T cells. As before, 
there is no selection towards CD4+ T cell predominance following MTX selection by day 21.  
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Figure 17 
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Figure 17 AThyRs select for transgenes of interest. The superior selection of DHFRFS is 
desirable for difficult to isolate genes of interest such as suicide genes. Suicide gene inducible 
caspase 9 (iC9) was designed to express with DHFRFS in the plasmid DFSiC9 shown in (A).  (B) 
This construct was tested in PBMC of 3 healthy donors stimulated with a 1: 1 ratio of OKT3-
loaded AaPC and treated with MTX from day 2 until day 7 when survival is shown. (C) T cells 
were electroporated with CD19-specific chimeric antigen receptor (CAR), DFSiC9, and SB 
transposase and expanded on CARL+ K562 in the presence of MTX for 21 days to select for 
each transgene. The expression of costimulatory T cell receptors CD4, CD8, and transgenes 
CAR and DHFRFS are shown in 21 day CARL expanded transgenic T cells in comparison to 
mock electroporated T cells expanded on OKT3-loaded AaPC clone.4. (D) The effect of MTX 
on cytotoxicity in DHFRFS+ CAR+ T cells was tested by stimulating CAR+ T cells in the presence 
or absence of MTX for 7 days after stimulation on day 14. Cytotoxicity was assessed by CRA 
on Day 21 using CD19 positive or CD19 negative murine lymphoma EL-4 cells. T cells were 
co-incubated with EL-4 at a 1 target: 5 effector ratio. (E) The functionality of iC9 was assessed 
on day 21 by resting T cells for 48 hours in 10 nM AP20187. T cells had previously been 
stimulated for 7 days in the presence or absence of MTX. Comparison of surviving CAR+ T 
cells is made to matched, un-treated cells. Experiments in C-E were performed with 4 normal 
donors and repeated twice. Significance for each comparison was initially determined by Two-
Way ANOVA followed by Sidak’s post-hoc analysis;   * = p < 0.05, ** = p <0.01, *** = p <0.001, 
**** = p <0.0001.  
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These cells also demonstrated cytotoxicity at the levels expected for the given 5 : 1 target to 
effector ratio (Figure 17D).[95] These findings agree with that of Jonnalagadda et al. who linked 
DHFRFS to CAR expression and noted cytotoxicity independent of MTX treatment.[82] Co-
expressing DHFRFS with iC9 rather than CAR added the potential to ablate T cells through the 
addition of iC9 chemical inducer of dimerization AP20187 (Figure 17E). The addition of 
AP20187 significantly depleted resting CAR+ T cells independent of MTX. This demonstrates 
that DFSiC9 can effectively select for iC9 expression and deplete genetically-modified T cells as 
necessary. The use of DHFRFS has the advantage of selecting transgene expression in T cells 
independent of antigen-specificity and antigen expression, making DHFRFS a more portable 
tool for use in a variety of T cell studies. 
DISCUSSION: 
Our work establishes 3 findings relevant to investigators designing genetically-modified 
T cell studies; 1) AThyRs rescue T cells from AThy toxicity mediated by 5-FU and anti-folates 
targeting DHFR and TYMS. 2) DHFRFS permits MTX-inducible increase in transgene 
expression that is thymidine dependent, and TYMSSS permits MTX-inducible decrease in 
transgene expression that is dihydrofolate dependent. 3) AThyRs can be used to positively 
select for transgenes of interest without the use of immunogenic genes or magnetic selection. 
To the first point, we demonstrate that combining AThyRs DHFRFS and TYMSSS leads 
to significant survival advantages for T cells treated with toxic concentrations of AThys: MTX, 
Pem, or 5-FU. These AThy drugs are regularly used to treat lung and colon cancer among 
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other common cancers, [85, 86] and our findings indicate that AThyRs can survive toxic AThy 
concentrations. It has been shown that myeloid derived suppressor cells, which suppress T cell 
targeting of cancer cells, are selectively depleted by 5-FU.[102] Likewise, in a mouse model 
combining 5-FU with an immunotherapeutic strategy, it was shown that 5-FU increases Fas 
expression on cancer cells and leads to improved targeting of cancer cells when the two 
therapies were combined, but not when either strategy was used alone.[103]  Thus, combining 
the immunomodulatory effects of chemotherapy like 5-FU with T cells resistant to the cytotoxic 
effects of 5-FU could substantially improve the anti-cancer response of the patient above that 
of either therapeutic used alone.  This supports further in vivo study of an autologous tumor 
and T cell system where the tumor is concurrently treated with AThys and AThyR+ T cells.  An 
in vivo model should resolve the issue of whether CD4+ T cell predominance in AThyR+ T cells 
persists and if it leads to any detrimental consequences of tumor clearance. As for the use of 
AThyRs to prevent anti-folate toxicity from MTX or Pem, we establish that MTX is more toxic to 
T cells than Pem and find that MTX susceptibility to < 1 µM MTX could be completely 
abrogated by the codon optimization of DHFRFS or by the addition of TYMSSS to DHFRFS in T 
cells. Concentrations of up to 1 µM MTX are achieved during the treatment of rheumatoid 
arthritis.[104] Higher doses of MTX are achieved in cancer chemotherapy (> 1mM MTX) with the 
use of leucovorin.[105] Leucovorin rescues thymidine synthesis through the same pathway as 
combination DHFRFS and TYMSSS. Thus, [DHFRFS & TYMSSS]+ T cells will likely resist 
cytotoxicity induced by the range of MTX experienced for both immune suppression and cancer 
treatment, but this remains to be tested in in vivo models. 
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Figure 18 
 
Figure 18 Post-transcriptional regulation of thymidine synthesis locks expression of 
DHFR to TYMS. MTX-induced increases in DHFR expression were inhibited by restoration of 
thymidine synthesis (TMP – thymidine monophosphate from UMP - uridine monophosphate). 
Likewise, MTX-induced decreases in TYMS expression were restored to normal levels by the 
restoration of DHFR activity reducing DHF – dihydrofolate to THF - tetrahydrofolate. These 
findings link expression of transgenic DHFR with transgenic TYMS. 5, 10 – 
methylenetetrahydrofolate (5,10 CH2THF) 
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With regard to the second finding, we establish that MTX can be used to regulate 
transgene expression either to higher or lower expression levels for a transgene expressed cis 
to DHFRFS or TYMSSS, but not [DHFRFS & TYMSSS]. We note that the increased expression of 
eGFP expressed cis to DHFRFS was blunted by the restoration of thymidine synthesis by 
TYMSSS. Likewise, we found that the decreased expression of eGFP expressed cis to TYMSSS 
was lost when DHFRFS permitted the reduction of dihydrofolate. Figure 18 depicts this 
relationship of the metabolite of one enzyme to the expression of the other. From this 
interrelationship it becomes clear that DHFR and TYMS expression is linked.  Thus, there is 
evidence that the correlated expression of DHFRFS and TYMSSS, noted in Figure 11C, is 
biologically linked. The influence of TYMS activity on DHFR expression[92] and the influence of 
DHFR activity on TYMS expression[96] are known, but the functional linkage in expression 
between DHFR and TYMS has not been examined to our knowledge. Clinical utility of the 
MTX-inducible increase or decrease of transgenes co-expressed cis to AThyR transgene is 
unknown. However, earlier studies in mice utilized transgenic tumor cells containing native 
DHFR linked to HSV-TK1 and found a 1.5- 4 fold increase of HSV-TK1 functionality with the 
addition of MTX.[98] Therefore, MTX-inducible positive or negative modulation of cis-transgenes 
could lead to clinically useful methods where MTX is used to modulate the spatial and temporal 
expression of dangerous but necessary transgenes, such as certain CAR or cytokine.[25] The 
correlated expression of DHFRFS with trans expressed TYMSSS may also have clinical utility in 
expressing proteins such as TCR α and β that need to be expressed at nearly equivalent 
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amounts and where the use of 2A mediated cleavage sites may adversely affect protein 
structure and function.[106] 
For the purpose of selecting genes of interest, AThyRs were compared to one of the 
earliest drug resistance transgenes – NeoR.[107] This was also the first drug resistance 
transgene used in humans.[43] It was found that DHFRFS is superior to NeoR in promoting 
survival, selection, and drug-dependent increases of expression for eGFP. Notably, DHFRFS 
and TYMSSS have lower immunogenicity as human proteins, and MTX can be used both in vitro 
and in vivo [46] to improve transgene selection whereas G418 cannot.[108-110] Our findings that 
DHFRFS can select for cells expressing important transgenes such as the suicide gene iC9 
makes DHFRFS and [DHFRFS & TYMSSS] a reasonable alternative to magnetic beads for 
selecting a gene or genes of interest. In fact, the potential to select for AThyR+ T cells in vivo 
using MTX suggests that transgene selection could be performed within the patient rather than 
ex vivo.  
In conclusion, the use of AThyR transgenes DHFRFS and TYMSSS alone or in 
combination provides a unique capacity to select for transgene expression within the bulk 
population, modulate the expression of cis as well as trans transgenes, and promote survival in 
toxic concentrations of AThys. Our findings broaden the potential use of DHFRFS in 
combination with TYMSSS to cancers such as lung, colon, breast, and pancreas that are in dire 
need of new therapeutic options. In a future application we seek to combine AThyRs with 
pancreatic cancer specific T cells to enhance anti-tumor efficacy. 
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CHAPTER 4: Development of pharmacological approaches to select 
or deplete Tregs 
INTRODUCTION: 
 Regulatory T cells (Treg) are a subset of T cells vital to the balance of the adaptive 
immune response. If Treg are deficient or defective, then autoimmunity develops.[111] If Treg are 
dominant within an environment, then immune-tolerance permits the outgrowth of tumors.[112] 
Thus, control of Treg is desirable for the treatment of a large number of human diseases falling 
under the category of autoimmunity or cancer. However, the rarity of this T cell subset[11] and 
the challenging nature of selecting for these cells, which are characterized by the expression of 
an intracellular transcription factor –FoxP3- in addition to other markers,[111, 113] makes studying 
how these cells are selectively expanded or depleted a difficult task.  
Selection of Treg is desirable for the treatment of autoimmunity and occurs with several 
therapeutics by differing mechanisms of action such as irradiation,[114] MTX, 5- fluorouracil (5-
FU),[115] 5-azacytidine,[116] and cilostamide.[117] These findings were described in vitro and in 
vivo using rodent models.[116-120] In humans, an increase in Treg was noted following the 
administration of multi-drug regimens to treat cancer.[121] A shared mechanism of action for 
preferential selection of Treg is not clear, but MTX appears to be a strong candidate for 
understanding how Treg selection is occurring. MTX has a known role in inhibiting purine 
metabolism [86] similar to cilostamide, thymidine synthesis similar to 5-FU, [86] and DNA 
methylation[122] similar to 5-azacytidine, each of which selects for Treg as noted.  MTX inhibits de 
novo purine synthesis upstream at Glycinamide ribonucleotide transformylase (GART), 
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downstream at 5-aminoimidazole-4-carboxamide riboside (AICAR) transformylase (AICARtf), 
de novo thymidine synthesis at thymidylate synthase (TYMS), and single carbon metabolism, 
which includes methylation, at dihydrofolate reductase (DHFR) (See Figure 19A).[86] Since 
MTX is first-line therapy in the treatment of severe rheumatoid arthritis[123] and GvHD 
prophylaxis,[124] discerning how MTX influences Treg selection is of clear importance. 
 Depletion or blocking of Treg is currently most effective using biological agents in the 
treatment of cancer.[112] This is exemplified by anti-CTLA-4 therapy, [125] which depends in part 
upon the inhibition of Treg.[126] Among non-biological agents, cyclophosphamide is thought to 
deplete Treg [112, 127, 128] in the treatment of cancer.[129, 130] However, this finding may be dose and 
time dependent[128][131] The mechanism of cyclophosphamide induced Treg depletion may be 
related to adenosine monophosphate (AMP) Kinase (AMPK) as cyclophosphamide is known to 
deplete levels of ATP within Treg,[127] and low levels of ATP are known to activate AMPK.[132] 
Recent findings of Treg depleting gene targets 3-hydroxy-3-methyl-glutaryl (HMG)-CoA 
reductase [133] and p300 [134] are also AMPK targets – further implicating AMPK in a pathway of 
Treg survival. In this study, we demonstrate AMPK signaling is enhanced in activated Treg, and 
we further demonstrate that AMPK target ribosomal translation via eukaryotic elongation factor 
– 2 (eEF2).[135][136] Interestingly, MTX potentiates activation of AMPK via the inhibition of 
AICARtf.[137] This suggests that an AMPK – eEF2 axis may be involved in the selection or 
depletion of Treg.  
To determine the influence of MTX on Treg selection, we utilize DHFRFS and TYMSSS 
capable of resisting MTX and 5-FU targeting of native DHFR or TYMS, respectively. We find 
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that alleviating thymidine blockade of MTX promotes Treg expansion, likely through inhibition of 
purine synthesis.  Further analysis of TCD4, FoxP3 selection by MTX and toxic agents targeting 
similar pathways suggests that inhibited purine synthesis is not the primary mechanism of Treg 
selection. Rather, inhibition of Treg replication by inhibited ribosomal protein translation appears 
to mediate selection in chemotherapy. Multiple drugs are known to inhibit ribosomal synthesis 
and translation,[99, 136] and rapamycin, a drug commonly used in Treg selection,[138] also inhibits 
translational initiation and ribosomal synthesis.[139] Our study elucidates a common pathway for 
the selection and depletion of Treg, and consequently develops a novel method to transgenically 
improve selection of Treg as well as a biochemical method to deplete Treg.  
MATERIALS AND METHODS: 
Cells and culture conditions: 
Cells: Healthy donor derived peripheral blood from MDACC Blood Bank, Houston, Texas, was 
subjected to density gradient centrifugation to isolate mononuclear cells which were either 
rested in complete media (CM) or frozen as previously outlined. The use of rested or frozen 
peripheral blood derived mononuclear cells (PBMC) is outlined in each experiment. T cells from 
PBMC were stimulated using thawed OKT3 antibody-loaded K562 clone #4, an activating and 
propagating cell (AaPC).[94]  The presence of mycoplasma was tested in AaPC before 
stimulation of T cells. Cell counting was accomplished by 0.1 % Trypan Blue (Sigma-Aldrich, 
T8154) exclusion using automated cell counting (Nexcelcom, Lawrence, MA). Cell Isolation 
was accomplished using magnetic bead based sorting with the CD4+, CD25+ Regulatory T Cell 
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Isolation Kit following the manufacturer’s instructions (Miltenyi Biotec, San Diego, CA, 130-091-
301). Briefly, CD4+ T cells were negatively selected before sorting one time with anti-CD25 
beads was used to differentiate between effector T cells (CD25neg) and Treg (CD25pos). 
Culture Conditions: Acellular stimulation was accomplished as previously described using 
soluble anti-CD3 – 30 ng/ mL, anti-CD28 – 100 ng/ mL, and human IL-2 – 50 IU/ mL, as 
previously described . When indicated, the following drugs were used: 5-FU, MTX, cisplatin 
(CDDP), pemetrexed, raltitrexed, G418, hygromycin B, zeocin, rapamycin, metformin,  AICARtf 
/ inosine monophosphate (IMP) cyclohydrolase (ATIC) dimerization inhibitor (iATIC) (Table 8).  
Acellular stimulation experiments received addition of toxic drug or treatment on the same day 
as stimulation.  
DNA expression plasmids: 
Selection vectors: FLAG-DHFRFS-2A-eGFP pSBSO (noted as DHFRFS-GFP (DG)), 
FLAG-TYMSSS-2A-eGFP pSBSO (noted as TYMSSS-GFP (TSG)), NLS-mCherry pSBSO 
(RFP), FLAG-TYMSSS-2A-NLS-mCherry pSBSO (noted as TYMSSS-RFP (TRG)),  Neomycin 
Resistance (NeoR)-2A-eGFP pSBSO (noted as NeoR-GFP (NRG)), and Myc-ffLuc-NeoR 
pSBSO (NRF), were designed constructed and utilized as previously described . Sleeping 
Beauty (SB) indirect/ direct repeat (IR/DR) sites were present in each construct to induce 
genomic integration with SB transposase. Each transgene was expressed by elongation factor 
1 alpha (EF1α) promoter. 
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Table 8 Chemical Agents 
 
Agent Manufacturer ID No. 
5-fluorouracil APP Pharmaceuticals, Schaumburg, IL NDC 63323-117-10 
Methotrexate Hospira, Lake Forest, IL NDC 61703-350-38 
CDDP Pfizer, New York, NY NDC 0069-0084-07 
Pemetrexed Lilly, Indianapolis, IN NDC 0002-7640-01 
Raltitrexed Abcam Biochemicals, Cambridge, MA Ab142974 
iATIC EMD Millipore 118490 
G418 Invivogen, San Diego, CA Ant-gn-1 
Hygromycin Invivogen Ant-hg-1 
Zeocin Invivogen Anti-zn-1 
Rapamycin Wyeth, Philadelphia, PA NDC 0008-1030-04 
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Genetic Transformation and Propagation of Cells: 
The Amaxa Nucleofector® II was utilized to transform human PBMC, where 1-2*107 
thawed PBMC were electroporated in Amaxa T cell Nucleofector solution using program U14, 
as previously described . The next day, PBMC were stimulated with CM with AaPC at a ratio of 
1: 1 including 50 IU/ mL IL-2. The co-culture of T cells and AaPC was maintained at 1*106 cells/ 
mL with each subsequent stimulation. Outgrowth of T cells was promoted by re-stimulated of 
co-cultures every 7 days with IL-2 and AaPC at the concentrations noted. Fresh IL-2 was 
added when media was changed between stimulations. During transgenic experiments, drugs 
were added 48 hours after co-culture initiation and maintained at the given concentration until 
day 14. After day 14, no drugs were added to T cell cultures.  
Western blot: 
When noted, T cells were removed from cultures for western blot by centrifugation of 
1*106 T cells, and rapid freezing of the cell pellet in liquid nitrogen. T cell pellets were lysed and 
prepared with 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 1mM 
phenylmethylsulfonyl fluoride, 150 mM p-nitrophenyl phosphate and 0.3 µM Aprotinin, pH 
7.4. SDS-PAGE separated proteins and primary antibodies noted in Table 9 were used to 
detect the presence of protein via chemiluminescence. 
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Table 9 Western Blot Antibodies  
Antibody Manufacturer Cat. No. Dilution 
AMPKα Cell Signaling Technology (CST), Danvers, MA 2603S 1: 1000 
p-AMPKα 
(T172) CST 2535S 1: 1000 
S6 CST 2317S 1: 1000 
p-S6 
(S235/236) CST 3945S 1:1500 
Actin Sigma A2228 1:10000 
Hsp-70 Santa Cruz Biotechnology, Dallas, TX SC-24 1:5000 
eEF2 LifeSpan Biosciences, Seattle, WA LS-B8940  
p-eEF2 (T56) LifeSpan Biosciences LS-C198899  
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Flow cytometry:  
Cultured  T cells were washed in FACS staining solution[95] before surface antibody 
staining was performed in FACS staining solution with fluorochrome-conjugated antibodies at 
4º C for at least 30 minutes. Intracellular transcription factor and cytokine staining utilized the 
FoxP3 / transcription factor staining buffer set manufacturer’s protocol (eBioscience, 00-5523-
00), and was performed following surface staining. The BD FACSCalibur (BD Biosciences) 
analyzed most samples expressing FoxP3. Antibody targets, concentrations, and 
manufacturers are listed in Table 10. Flow cytometry data analysis utilized FlowJo v 10.0.5 
(Tree Star Inc., Ashland, OR). Flow cytometric imaging of cells stained for phosphorylated 
antigens was accomplished using the ImageStreamX Mark II (Amnis, Seattle, WA) with the 
following protocol; after surface staining, samples were fixed in 100% methanol (Sigma) for 1 
hour at 4º C before washing and staining in FoxP3 / transcription factor staining buffer set wash 
buffer as outlined by the manufacturer’s protocol. Analysis of image cytometry data utilized 
Amnis IDEAS v 6.0. 
Thymidine Incorporation Assay:  
A thymidine incorporation assay was performed with anti-CD3/ CD28 and IL-2 used to 
stimulate each well containing 2 * 105 viable cells.  Varying ratios of effector T cells (Teff) to Treg 
were combined in each well and all wells were run in triplicate in U-bottom 96 well plates. At 48 
hours 1 µCi [3H] Thymidine (Perkin-Elmer, Waltham, MA) was added to each well, and 24 
hours later the cells were assessed for radioactivity on a Top Count NXT (Perkin-Elmer). Treg 
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mediated suppression of growth was determined by the following equation: (No Treatment Teff 
[cpm] - (Treg & No Treatment Teff [cpm])) / No Treatment Teff [cpm].  
Statistical Analysis: 
Graphical representation and statistical analysis of data was performed with Prism v6.0 
(Graph Pad Software Inc., La Jolla, Ca). One-Way ANOVA was used when appropriate with 
Tukey’s or Dunnett’s multiple comparison tests as applicable, non-Gaussian distributions were 
assessed by the Kruskall-Wallis test followed by Dunn’s multiple comparison test. Total cell 
counts and expression data involving TCD4, FoxP3 tended to be non-Gaussian in distribution. 
Single variable tests (experimental vs. control) were made using the Mann-Whitney test. 
Statistical significance was designated as α < 0.05. 
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Table 10 Flow Cytometry Antibodies  
Antibody Manufacturer Cat. No.  Dilution 
CD3-APC BD Pharmingen 340661 1:33 
CD3-PerCP-Cy5.5 BD Pharmingen 340949 1:33 
CD4 FITC BD Pharmingen 340133 1:33 
CD4 -PE BD Pharmingen 347327 1:33 
CD4-PerCP-Cy5.5 BD Pharmingen 341645 1:33 
CD8-APC BD Pharmingen 340659 1:33 
CD25-APC BD Pharmingen 555434 1:33 
CD39-APC BD Pharmingen 560239 1:33 
CD45RO-APC BD Pharmingen 559865 1:33 
CD152-APC BD Pharmingen 555855 1:33 
KI-67-AF647 BD Pharmingen 561126 1:50 
Annexin V BD Pharmingen 556422 1:20 
7-AAD BD Pharmingen 559925 1:20 
Propidium Iodide BD Pharmingen 556463  
FoxP3-PE eBiosciences 12-4777-42 1:20 
Helios-APC Biolegend 137222 1:05 
LAP-APC Biolegend 349608 1:20 
IFN-g-APC Biolegend 502516 1:20 
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IL-2-APC Biolegend 500315 1:20 
p-eEF2 (T56) 
LifeSpan 
Biosciences LS-C198899 1:20 
p-AMPKα (T172) AbCam Ab133448 1:20 
CD4-Pacific Blue BD Pharmingen 558116 1:33 
p-S6 (S244) – 
AF647 BD Pharmingen 560465 1:20 
Goat anti-Rabbit – 
AF488 Life Technologies A-11034 1:100 
 
 
 
 
 
 
 
 
 
 
108 
 
RESULTS:  
Drug selection of TCD4, FoxP3 by MTX occurs in part through toxicity.  
In order to determine how MTX contributes to the selection of TCD4, FoxP3, freshly derived 
PBMC were stimulated with anti-CD3/ CD28 antibodies and IL-2 in the presence of cytotoxic 
drugs or lethal γ-irradiation. After 7 days there was a significant difference in survival markers 
Annexin V and 7-AAD in stimulated T cells receiving any cytotoxic insult with stimulation 
(Figure 19B-I). The selection of TCD4, FoxP3 was not as consistent as cytotoxicity. Following 7 
days of stimulation, 2 Grey γ-irradiation significantly increased the amount of TCD4, FoxP3 in the 
surviving population (Figure 19B-II). This lethal treatment did not target a common pathway 
being considered, nor did cisplatin, yet both increased TCD4, FoxP3. However, the TCD4, FoxP3 
increase induced by cisplatin is insignificant. The only significant increases derived from drugs 
in this experiment were 5-FU and MTX, recapitulating earlier findings.[115] With the exception of 
ribosomal elongation inhibitor G418,[140] each cytotoxic treatment appeared to increase the 
percentage of surviving TCD4, FoxP3. This pattern of increasing TCD4, FoxP3 percentage in the face of 
varied cytotoxic insult suggests a common pathway that can be enhanced by certain drugs. 
This pathway is likely related to the slower proliferation rate of Treg, [141] and appears to be 
ribosomally mediated as G418 can inhibit this general trend of increasing TCD4, FoxP3 percentage. 
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Figure 19 
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Figure 19 Drug selection of TCD4, FoxP3 by MTX occurs in part through toxicity. The known 
selection of TCD4, FoxP3 by MTX was analyzed by targeting enzymes that contribute to the action 
of MTX. As TCD4, FoxP3 are a rare component of PBMC, drug based inhibition was originally 
sought to analyze the phenomenon. Multiple drugs with actions similar to MTX were used to 
assay for the selection of TCD4, FoxP3. In this case, γ-irradiation, G418, and cisplatin (CDDP) were 
used for controls as none of those treatments act on the known enzymatic targets of MTX. The 
association of each drug to the enzyme targets of MTX is shown in A. PBMC stimulated with 
anti-CD3/ CD28 and soluble human IL-2 were given lethal doses of each treatment and 
assayed after 7 days for viability B-I. These treatments resulted in variable selection for TCD4, 
FoxP3 on day 7 as seen in B-II. The inability of folate analogs targeting DHFR, TYMS, or GARFT 
to significantly select for TCD4, FoxP3 suggested that inhibition of ATIC contributes to this 
selection. A dose dependence study followed analyzing the contribution of ATIC inhibitor in the 
selection of TCD4, FoxP3. The study in B-II noted that G418 depleted TCD4, FoxP3, thus, this was 
used as a negative control while the known selection of TCD4, FoxP3 by rapamycin (Rapa) was a 
positive control. A non-folate analog known to inhibit ATIC (iATIC) was used as a specific 
inhibitor of ATIC. The cytotoxicity of G418 C-I, MTX D-I, iATIC E-I, and Rapa F-I is shown in 
the top panel while the selection for TCD4, FoxP3 is shown in the bottom panel for G418 C-II, MTX 
D-II, iATIC E-II, and Rapa F-II. The drug iATIC did not select for TCD4, FoxP3, ruling out this 
pathway as the primary means of MTX selection. However, visual inspection of the flow plots 
for CD4 and FoxP3 expression in G, represented by one donor, demonstrate that FoxP3 
expression was enhanced by iATIC similar to the action of Rapa, suggesting that MTX 
111 
 
selection relies in part on cytotoxicity and in part by inhibition of ATIC to enhance selection of 
TCD4, FoxP3. All assays used 4-7 donors independently repeated 2-3 times. Statistical significance 
was assessed using One-Way ANOVA for viability and Kruskall-Wallis test for percentage of 
TCD4, FoxP3; * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001. 
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The findings of Treg depletion with G418 and Treg selection by MTX were further 
evaluated for dose dependence by stimulating thawed PBMC with anti-CD3/CD28 + IL-2 for 7 
days, as before. G418 was significantly cytotoxic at all doses tested, but significantly depleted 
TCD4, FoxP3 at two moderate drug doses (Figure 19C). MTX was also cytotoxic at all doses 
tested, but had significant elevation of TCD4, FoxP3 at lower doses (Figure 19D). Rapamycin 
(Rapa) was used as a Treg selection control[138] and showed similar TCD4, FoxP3 selection at a 
moderate drug concentration independent of cytotoxicity, which only occurred at the highest 
doses (Figure 19F). The selection for or against Treg at moderate drug doses rather than higher 
doses suggests that Treg have a narrow therapeutic window for drug induced selection or 
depletion. A specific inhibitor of ATIC [142] was used to test whether MTX mediates selection of 
TCD4, FoxP3 through inhibition of ATIC. Inhibition of AICARtf or the heterodimeric complex ATIC, 
in which AICARtf is found, increases AICAR. AICAR is known to activate AMPK,[142] and it is 
known that activated AMPK inhibits ribosomal activity through inhibition of mTORC1[136] and 
eukaryotic elongation factor 2 (eEF2).[139] Figure 19E demonstrates that ATIC inhibition alone 
was neither cytotoxic nor selective for TCD4, FoxP3. Further analysis of flow plots represented by 
the same donor in Figure 19G show expression of CD4 and FoxP3 for several of the drugs 
used. Use of iATIC characteristically mediated increased expression of FoxP3 in CD4+ T cells 
similar to that of Rapa, but did not inhibit proliferation of FoxP3neg T cells as MTX, G418, or 
Rapa. Thus, iATIC enhanced FoxP3 expression in CD4+ T cells but diluted these cells by 
permitting proliferation of FoxP3neg T cells. It appears that MTX mediated selection of TCD4, FoxP3 
occurs by depletion of rapidly proliferating effector T cells and enhancement of FoxP3 
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expression via a pathway similar to Rapa that includes ribosomal inhibition. The increased 
susceptibility of Tregs to ribosomal inhibitor G418 solidifies this relationship between enhanced 
FoxP3 expression and increased susceptibility to ribosomal inhibition. 
Tregs are preferentially expanded in primary T cells resistant to the anti-folate and anti-
thymidine actions of MTX.  
Prior studies by Jonnalagadda et al. have demonstrated the potential of DHFRFS to 
promote T cell survival in the presence of MTX.[46, 82] We previously performed selection studies 
of DHFRFS transgene in bulk human PBMC using MTX and found CD4+ T cells predominance. 
The preference of multiple drug selection vectors to selectively propagate CD4+ T cells in the 
same way suggested a common phenomenon. It was hypothesized that regulatory T cells were 
inhibiting CD8+ T cells proliferation following drug selection.  To test this hypothesis, drug 
resistant T cells were derived by transformation with DHFRFS, TYMSSS, NeoR, or a 
combination, and numerically expanded as previously described. Briefly, transformed T cells 
were selected in the presence of 0.1 µM MTX, 5 µM 5-FU, or 1.6 mM G418 as designated from 
day 2 to 14 while stimulation with OKT3-loaded AaPC and 50 IU / mL IL-2 occurred every 7 
days until day 35.[94]  
Initial testing for Tregs by elevated expression of FoxP3 in the CD4+ T cell population 
demonstrated there was a significant TCD4, FoxP3 percentage increase in DHFRFS expressing T 
cells. Selection using MTX in comparison to mock-electroporated (No DNA) T cells on Day 21 
showed this increase (Figure 20A), and this increase persisted to Day 35 when 5-FU was 
combined with MTX during selection (Figure 21A). The transgenic T cells were almost entirely 
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CD4+ in each experimental population after selection, but the predominance of Tregs appeared 
to often exceed the 5-10% typically found in the un-manipulated CD4+ T cell compartment.[141] 
Markers of Treg function were also assessed. Low IL-2 expression [113] is a known trait of Tregs 
and is assessed with FoxP3 expression. The percentage of the T cell population with a 
FoxP3pos, IL-2neg expression pattern is shown in Figure 21B. Expression of latency associated 
peptide (LAP) - a part of the TGF-β complex [143] and strongly associated with activated Treg, and 
is seen in Figure 21C. The protein CTLA-4[113] mediates intercellular inhibition of effector T cell 
responses and is shown by FoxP3+, CTLA4+ expression in Figure 21D. These findings help to 
corroborate whether the TCD4, FoxP3 in each experiment were Treg as donor to donor variability 
and low TCD4, FoxP3 numbers made suppression assays an ineffective Treg measure. 
The transgenes DHFRFS and TYMSSS were compared individually and in combination to 
the control selection vector NeoR and un-treated No DNA T cells. Selection towards Treg in this 
experiment may be noted in Figure 21A, B, C –I. This experiment demonstrated that [DHFRFS-
GFP (DG) & TYMSSS-RFP (TSR)]+ T cells selected in MTX + 5-FU had an increased population 
of cells characteristic of Treg when compared to mock-transformed T cells. To further elucidate 
the contribution of DHFRFS and TYMSSS to Treg selection, NeoR was co-electroporated with 
DHFRFS, TYMSSS, or the combination. The addition of NeoR permitted equivalent selection of 
DHFRFS, TYMSSS, and the combination in all T cell populations. With un-transformed T cells 
removed, it became clear that DHFRFS alone, but not TYMSSS alone could select for cells 
characteristic of Tregs (Figure 21A, B, and C –II). [DG & TSR]+ T cells continued to select for 
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Figure 20 
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Figure 20 Correlative findings in the selection of Tregs from primary T cells through 
resistance to the anti-DHFR and anti-TYMS actions of MTX. Selection of TCD4, FoxP3 was 
assessed at day 21 in each experiment. The selection of TCD4, FoxP3 in the experiment 
corresponding to column I of Figure 21 is shown in A. It is notable for the rescue of TCD4, FoxP3 
with NeoR and early selection of TCD4, FoxP3 with MTX selection of DHFRFS. Flow plots in B show 
co-expression of FoxP3 with IL-2 top row, LAP middle row, or CTLA-4 bottom row for the 
same experiment after stimulation on Day 35. This experiment utilized 5 donors and was 
independently repeated twice. Significance was assessed by Two-Way ANOVA and Sidak’s 
post-hoc; * = p < 0.05, ** = p < 0.01.   
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Figure 21 
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Figure 21 Primary T cells resistant to the anti-DHFR and anti-TYMS actions of MTX 
preferentially expand Tregs. Primary T cells were electroporated with DHFRFS and TYMSSS 
transgenes resistant to the anti-DHFR and anti-TYMS actions of MTX, respectively, in order to 
assess the contribution of each pathway to the selection of TCD4, FoxP3.  T cells were 
electroporated with plasmids expressing drug resistant transgenes and stimulated with artificial 
antigen presenting cells (AaPCs) weekly at a 1: 1 ratio. T cells were selected for 2 weeks in the 
combined with TYMSSS-2A-RFP (TSR) and selected using both MTX and 5FU, or control 
selection vector NeoR-2A-GFP (NRG) selected with G418. Selection of TYMSSS by 5-FU was 
incomplete. Thus, ffLuc-2A-NeoR (NRF) vector was included with the MTX resistant 
transgenes DG, TSG, or [DG & TSR] to remove untransformed T cells in the experiments 
shown in column II. Equivalent selection for each transgene showed that MTX enhanced 
selected for Treg in the presence of MTX resistant DHFR. It was still uncertain whether the 
enzymatic activity of TYMS or 5-FU played a part in the selection of Treg. Therefore, the 
experiment shown in column III was performed to test the influence of TYMS inhibition in the 
selection of Treg.  Selection of Treg phenotype was found to be associated with 5-FU, but 
independent of TYMS activity. The Kruskall-Wallis test was used to assess differences 
between groups for 5-6 biologic replicates and tests were independently repeated twice; * = p < 
0.05, ** = p <0.01.   
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cells with Treg features. Finally, the contribution of TYMSSS to the selection of Treg by DHFRFS 
was assessed by co-electroporation of TSR or a control vector- RFP. The characteristics of 
Tregs from this experiment are shown in Figure 21A, B, and C–III. This experiment 
demonstrates that selection of DHFRFS with MTX can enhance outgrowth of Treg and that 5-FU 
enhances this selection independent of TYMSSS.  Selection of Treg required folate rescue by 
DHFRFS. This is expected as folate is known to be crucial to Treg survival.[144] Surprisingly, 
selection of Treg did not require de novo thymidine synthesis as TYMSSS, which alleviates MTX 
and 5-FU inhibition of TYMS, was dispensable.     
Previous findings showed survival and toxicity of 5-FU in PBMC is mediated by TYMS 
and an alternative mechanism.[145] RNA inhibition, [85] including inhibition of ribosomal synthesis, 
[99]
 is a known alternative mechanism. Combining the known mechanisms of Treg selecting 
drugs MTX, 5-FU, and rapamycin yielded the diagram in Figure 22, which details how each 
drug interacts with ribosomal function. It was noted in an experiment depicted in Figure 20A 
that Neomycin resistance gene rescued TCD4, FoxP3 from the treatment of G418. This finding 
suggests that a specific action of G418 is responsible for TCD4, FoxP3 depletion, and this 
phenomenon was further explored.    
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Figure 22 
 
Figure 22 Diagrammatic representation of biochemical and protein interactions thought 
to influence selection of Treg 
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Ribosomal Inhibition by aminoglycoside G418 selectively depletes replicating TCD4, FoxP3.  
Thawed PBMC were activated with anti-CD3/CD28 + IL-2 for 7 days in the presence of 
alternative doses of G418, Hygromycin B - a different aminoglycoside,[146] Zeocin – a DNA 
targeting antibiotic, and Rapa to assess the dose dependent selection or depletion of TCD4, FoxP3 
by aminoglycosides (Figure 23A). Depletion of TCD4, FoxP3 is again noted in the presence of 
aminoglycoside G418. The alternative aminoglycoside - hygromycin – developed an 
insignificant increase in TCD4, FoxP3 at 0.2 mM hygromycin. This increase significantly decreased 
with higher doses of hygromycin - 1.5 and 2.3 mM. Hygromycin showed no significant depletion 
of TCD4, FoxP3 from untreated control.  
This dose dependent depletion of TCD4, FoxP3 is consistent with that seen for G418, and 
was not noted with increasing doses Zeocin or Rapa. An increase of TCD4, FoxP3 was noted with 
increasing doses of Zeocin, yet this was insignificant, similar to that seen for other cytotoxic 
drugs in Figure 19B-II. A representative flow plot of CD4 and FoxP3 expression from the same 
donor can be seen in Figure 23B. Here, the trends can be visualized.  
It was considered that polyclonal stimulation may play some part in the G418 depletion 
of TCD4, FoxP3. To test this, PBMC were rested in CM for 9 days after thawing +/- G418 and 
tested for the presence of TCD4, FoxP3. Significant depletion of TCD4, FoxP3 by G418 persisted under 
resting conditions (Figure 23C – left panel). This was replication dependent as 
CD4+,FoxP3+,Ki-67+ cells showed significant G418 mediated depletion while CD4+,FoxP3+,Ki-
67neg cells were not significantly depleted by the same post-Hoc measure (Figure 23C – right  
122 
 
Figure 23 
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Figure 23 Ribosomal Inhibition by aminoglycosides selectively depletes replicating TCD4, 
FoxP3. Prior experiments demonstrated that G418 depleted TCD4, FoxP3 in stimulated bulk PBMC. It 
was then tested whether this action of G418 included other drugs within the aminoglycoside 
class. G418 and hygromycin are aminoglycoside antibiotics known to inhibit translational 
elongation. Zeocin is an antibiotic that does not target the ribosome. Thawed PBMC were 
stimulated with anti- CD3/ CD28 and IL-2 in the presence of increasing concentrations of G418, 
hygromycin, zeocin, or rapamycin for 7 days and the selection for TCD4, FoxP3 is shown in A. Flow 
plots of FoxP3 and CD4 expression in B show the representative trends for one donor following 
the use of each drug. The loss of TCD4, FoxP3 was tested in un-stimulated, thawed PBMC over the 
course of 9 days with or without G418 as shown in C - top panel while C - bottom panel 
shows the effects of G418 on proliferating and non-proliferating TCD4, FoxP3 as indicated by Ki-67. 
Representative flow plots for one donor demonstrate the effect of G418 on CD4 and FoxP3 
expression in D - top panel while FoxP3 and Ki-67 expression are shown in D - bottom panel. 
Gentamicin is an FDA approved aminoglycoside antibiotic and was subsequently tested in 
comparison to G418 for depletion of TCD4, FoxP3 over a 7 day period. All experiments were 
performed with 6 normal donors and repeated independently twice. Kruskall-Wallis was used 
for A, Mann-Whitney used for C – top panel, and Two-Way ANOVA with Sidak’s post-hoc or 
post-hoc Mann-Whitney t-tests in C - bottom panel, One-Way ANOVA with Sidak’s post-hoc in 
E; * = p < 0.05, ** = p < 0.01, *** = p < 0.001 # = p< 0.05 for post-hoc t-test. 
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panel). Representative flow diagrams of resting PBMC in Figure 23D – upper panel show the 
loss in expression of FoxP3 for CD4+ T cells after treatment with G418. An alternative view of 
Ki-67 and FoxP3 expression in Figure 23D – lower panel demonstrates that FoxP3neg T cells 
continue to proliferate in the presence of G418, further supporting the selective targeting of 
G418 to TCD4, FoxP3 at this concentration.  Thus, proliferating TCD4, FoxP3 are depleted following 
treatment with aminoglycoside G418.  
As G418 and hygromycin are considered toxic to live animals, gentamicin, an 
aminoglycoside well known for its use in humans and animal models,[147] was tested for 
selective TCD4, FoxP3 depletion. Figure 23E depicts this depletion of TCD4, FoxP3 in resting PBMC 
after 7 days and demonstrates the consistent action of aminoglycosides in depleting TCD4, FoxP3. 
It was next tested whether depletion of TCD4, FoxP3 corresponded with a loss of Treg marker 
expression or selective Treg toxicity. 
Sorted Treg differentiate the effects of MTX, 5-FU, and G418 on selection in bulk PBMC.  
Magnetic sorting for CD4 and CD25 expressing PBMC yielded a CD4+ CD25+ 
population that is widely considered to contain Treg, and a CD25neg population of effector T cells 
(Teff).[113] These populations were treated with the same concentrations of MTX, 5-FU, G418, or 
no treatment, as above, for the first 7 days of co-culture with AaPC. After this period of time, 
co-culture continued without drug by stimulating with AaPC every 7 days until Day 21. Cells 
were assayed at this time for expression of CD25, CTLA-4, LAP, and IL-2, as before. The 
experimental outline can be seen in Figure 24A. A [3H] thymidine incorporation assay was also 
performed to determine the effect of each drug on the functionality of propagated Treg.     
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Figure 24 The effects of MTX, 5-FU, and G418 in sorted Treg. PBMC were depleted of 
CD4neg cells and the remaining CD4+ cells were magnetically separated by CD25 with the 
CD25+ cells cultured as Treg and CD25neg cells cultured as Teff. Each group of T cells was co-
cultured as before with AaPC at a 1:1 ratio and stimulated weekly for 3 weeks. The Treg and Teff 
were treated with MTX, 5-FU, or G418 as before for 7 days before stimulating without drug for 
the remaining 2 weeks of the experiment, which is diagrammatically shown in A. On Day 21, 
markers and activity of Treg were assessed to determine the contribution of each drug to 
selection or depletion of Treg, and the live TCD4, FoxP3 on Day 21 are shown in B. Each group of T 
cells was then stimulated to assess expression of known Treg markers. After stimulating with 
soluble anti-CD3/ CD28 and IL-2 for 48 hours T cells were assessed for co-expression of 
FoxP3 with CD25 in C – I, FoxP3 with CTLA-4 in C- II, and FoxP3 with LAP in C – IV. Six hours 
of stimulation with PMA/ ionomycin was used to assess loss of IL-2 secretion in FoxP3 
expressing T cells, C – III.  A 72 hour suppression assay was performed by mixing treated Treg 
with untreated Teff and looking at uptake of [3H] Thymidine at two separate concentrations, 
shown in D. This experiment was performed with 5 normal donors and repeated twice. All 
experiments were assessed with Two-Way ANOVA and significance was determined by 
Sidak’s post-hoc analysis; * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001.  
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When the surviving CD4+ cells were assayed on day 21 it was found that no drug 
significantly selected for TCD4, FoxP3 in the Teff compartment, nor did MTX and 5-FU improve 
selection for TCD4, FoxP3 in the Treg compartment (Figure 24B). The most consistent finding was 
that G418 persistently decreased surviving Treg following drug treatment. This was 
demonstrated by loss of surviving TCD4, FoxP3 (Figure 24B). Treg markers such as CD25 (Figure 
24C-I), CTLA-4 (Figure 24C – II), decreased IL-2 expression (Figure 24C – III), or LAP 
(Figure 24C – IV), in combination with FoxP3 expression was also decreased following 
stimulation on day 21. Thus, Treg are lost, likely due to toxicity of G418, rather than inhibited as 
2 weeks of growth promoting co-culture conditions could not sufficiently restore Tregs following 
G418 treatment.  
The Treg promoting properties of MTX and 5-FU appeared to depend in part upon the 
presence of Teff, as the enhanced selection of TCD4, FoxP3 was no longer noticeable after Teff were 
removed from the culture system (Figure 24B). The improved selection towards Treg 
phenotypes may have been accomplished by depletion of Teff which are known to contaminate 
Treg sorting.[113] It is likely that the ability of Treg to survive the cytotoxic insult of MTX or 5-FU in 
comparison to Teff was a primary component of the enhanced selection. Although there was a 
trend towards improved selection of Treg phenotypes (Figure 24C – I, II, III) when MTX or 5-FU 
was used, there was no significant difference for expression of CD25, CTLA-4, or loss of IL-2.  
However, the Treg- specific marker LAP was significantly increased by early treatment with MTX 
or 5-FU (Figure 24C – IV). As LAP was the only increased marker of those assayed, it is likely 
that LAP and the associated expression of TGF-β [143] was the probable cause for improved 
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suppression of MTX and 5-FU treated Treg above untreated Treg (Figure 24D). Thus, MTX and 
5-FU appear to have two components in enhancing selection of Treg: 1) Teff are selectively 
depleted by MTX and 5-FU, and 2) MTX and 5-FU increase the expression of LAP weeks after 
treatment.  
Stimulation of TCD4, FoxP3 enhances AMPK activation and leads to inhibition of eEF2 – a 
factor essential to translational elongation.  
AMPK is hypothesized to play a role in selection of TCD4, FoxP3, as noted above (Figure 
22). Furthermore, we hypothesized that enhanced activation of AMPK leads to inhibition of 
eEF2 in TCD4, FoxP3.[135] Preferential inhibition of translational elongation could explain selection 
for TCD4, FoxP3 in the presence of many cytotoxic drugs and depletion of TCD4, FoxP3 in the presence 
of inhibitors of translational elongation. We tested this hypothesis by assessing phosphorylation 
of AMPK 24 hours after activation of PBMC using flow cytometry (Figure 25A & B) and 
imaging cytometry (Figure 25C). The phosphorylation of AMPK on T172 indicates 
activation,[136] and was enhanced in stimulated over unstimulated TCD4, FoxP3. This enhanced 
activation of AMPK was increased in CD4+, FoxP3neg T cells  (Figure 25A – upper panel) as 
well, but the significant increase (p = 0.03 by t-test) did not persist following post-hoc analysis. 
Likewise, flow plots of activated AMPK with FoxP3 show this enhancement of AMPK activation 
is much more noticeable in the FoxP3-expressing subset (Figure 25B – upper panel).[148] A 
marker of translational initiation –S6 – is susceptible to mTOR regulation, and is 
phosphorylated when active.[139]  Phosphorylation of S6 (p-S6) was significantly enhanced in 
TCD4, FoxP3 following stimulation (Figure 25A – lower panel), which was previously shown by 
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Cabone et al.[149] While p-S6 increased in the FoxP3neg T cells (p = 0.01 by t-test), this increase 
was not significant following post-hoc analysis. The enhancement of p-S6 is observable in the 
representative flow plot for Figure 25B – lower panel. The activation of metabolic regulators 
AMPK and S6 was enhanced in both FoxP3+ and FoxP3neg CD4+ T cells following activation, 
but the increase was only significant in TCD4, FoxP3 in a Two-Way ANOVA with post-hoc Sidak’s 
test. The increased activation of AMPK and S6 following activation of TCD4, FoxP3 can be seen 
with image cytometry profiles shown in Figure 25D before – top panel – and after stimulation 
with anti-CD3/ CD28 and IL-2– bottom panel. The same compensation and visualization were 
applied to each panel making the top and bottom panels comparable.   
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Figure 25 
 
 
 
131 
 
Figure 25 Stimulation of TCD4, FoxP3 enhances AMPK activation and leads to inhibition of 
translational elongation factor eEF2. AMPK was hypothesized to mediate selection of TCD4, 
FoxP3 under cytotoxic conditions. PBMC were stimulated with or without anti- CD3/ CD28 and IL-
2 for 24 hours and flow cytometry was used to assess phosphorylation status of AMPK in TCD4, 
FoxP3. Differentiation of TCD4, FoxP3 from CD4+ CD25neg T cells was accomplished by gating in the 
stimulated and unstimulated experiments. A – top panel, depicts the mean fluorescence 
intensity (MFI) of AMPK activated by phosphorylation at T172 after stimulation while A – lower 
panel depicts the MFI of activated S6 by phosphorylation at sites S235/ S236. A flow plot 
depicting the changes in phosphorylation for TCD4, FoxP3 and CD4+ CD25neg T cells is seen in B – 
upper panel for AMPK and B – lower panel for S6 with respect to FoxP3 expression in gated 
CD4+ cells. An image cytometry gallery in C shows fluorescent and morphologic changes in 
TCD4, FoxP3 following stimulation. Activation of AMPK was found to be more robust in TCD4, FoxP3 
and it was further hypothesized that this activation led to preferential inhibition of translation 
and cell cycle progression by inactivation of translational elongation through eEF2. Inhibitory 
phosphorylation of eEF2 at T56 was assessed following 24 hours of stimulation, as before. An 
image cytometer was used to analyze p-eEF2 T56 MFI and depicts an increase unique to 
activate TCD4, FoxP3 in D. This difference from CD4+ FoxP3neg T cells is shown with an image 
cytometry gallery in E. All experiments were repeated independently at least twice with 6 
biological replicates. Two-Way ANOVA with Sidak’s post-hoc used in all analyses; * = p < 0.05, 
** = p < 0.01.   
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Enhanced activation of AMPK in TCD4, FoxP3 suggests translational elongation may be 
inhibited by phosphorylation of eEF2 and could account for the increased survival of TCD4, FoxP3 
in the presence of cytotoxic drugs and susceptibility to inhibitors of translational elongation, like 
aminoglycosides. We performed the same experiment as in Figure 25 A-C to assess the 
inactivation of eEF2 by phosphorylation at T56.[135] Image cytometry was used to quantify and 
visualize all events. Figure 25D demonstrates a significant increase in phosphorylation of eEF2 
in the same subset of T cells - TCD4, FoxP3 - following stimulation. Also, inhibitory phosphorylation 
of eEF2 was significantly increased above stimulated FoxP3neg T cells, which was not noted 
with AMPK or S6 phosphorylation. The increased phosphorylation of eEF2 only in stimulated 
TCD4, FoxP3 suggests that TCD4, FoxP3 would have decreased replicative capacity upon stimulation, 
as shown by Cao et al.[141] As decreased levels of active eEF2 inhibit progression through the 
cell cycle, [150] it also suggests that increased phosphorylation of eEF2 may account for the 
survival of TCD4, FoxP3 in cytotoxic environments, which was noted in Figure 19. Similarly, 
decreased translational capacity would make TCD4, FoxP3 increasingly susceptible to inhibitors of 
translational elongation, as was shown with aminoglycosides in Figure 23. Therefore, the 
activity of eEF2 may be the primary factor influencing both selection and depletion of Treg in 
these studies.  
DISCUSSION: 
 In this study, we further the understanding of TCD4, FoxP3 selection by MTX and 5-FU in 
humans, and determine that these cells constitute Treg by functional expression parameters of 
CD25, CTLA-4, LAP, and loss of IL-2. Prior studies by Tohyama et al., [115] in human cells 
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described this phenomenon but had not determined how these drugs enhanced selection of 
TCD4, FoxP3. Using recently described transgenes resistant to the actions of MTX and 5-FU on 
DHFR and TYMS, we developed an understanding that each drug operates independently of 
folate and thymidine synthesis to select for Treg. While the action of MTX on DHFR and the 
action or 5-FU on TYMS are the commonly understood mechanisms for anti-cancer efficacy, 
both drugs have alternative targets that promote tumor killing.[85, 86] Our study demonstrates that 
these alternative actions of each drug promote a Treg phenotype in surviving cells. Prior findings 
show MTX enhances AMPK activation through the inhibition of AICARtf and accumulation of 
AICAR which activates AMPK.[137] This action of MTX was hypothesized to promote Tregs, [123] 
but we found that specific inhibition of AICAR synthesis was neither toxic to T cells nor 
selective for TCD4, FoxP3. This essentially ruled out AICARtf inhibition as the primary means of Treg 
selection. However, FoxP3 expression in TCD4, FoxP3 was enhanced by the specific action of 
AICARtf inhibition, suggesting some action of AMPK may improve Treg phenotype. Isolated Treg 
studies resolved this issue by determining that the action of MTX was twofold. 1) Selection of 
Treg is dependent on the depletion of Teff, as removal of Teff prevents the selective increase of 
Treg following MTX treatment. 2) The action of MTX does enhance Treg functional activity in 
some regard as LAP expression and suppression of Teff proliferation were increased above 
untreated Treg. The activation of AMPK in the absence of folate depletion by MTX was achieved 
in the transgenic T cell experiments and increased the percent of T cells with a functional Treg 
phenotype. Thus, MTX depletes Teff and promotes an immunosuppressive Treg phenotype. 
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Use of MTX consistently depleted CD8+ T cells in transgenic experiments to leave 
primarily CD4+ T cells even when MTX toxicity was rescued by resistant DHFRFS and/ or 
TYMSSS. This suggests that CD8+ T cells may be more susceptible to AMPK signaling. A 
higher replication rate could exceed the capacity of the transgene to rescue transgenic cells. 
This is more likely the case as both 5-FU and G418 also resulted in CD4+ T cell predominance 
following transgenic rescue, although neither drug is known to signal through AMPK. A 
decreased replicative rate of Treg is also supported by the finding of increased AMPK activation 
and increased eEF2 inactivation.  Translational elongation factor eEF2 is the primary means of 
ribosomal elongation, [135] and inhibition would significantly impede translation and progress 
towards cell division.[150] Therefore, activated Treg grow slower and take longer to succumb to 
any genotoxic insult, even one which will eventually kill all cells. This is consistent with findings 
in this study and others, where pan-cytotoxic γ-irradiation or chemotherapy selected for Treg.[114] 
The selective inhibition of eEF2 in Treg has clear biological implications in slowing suppressive 
mechanisms during early poly-clonal activation to permit the development of a sufficient 
immune response.    
While the action of MTX in selecting for Treg appears to be well delineated by our 
experiments, the action of 5-FU in Treg selection is not as clear.  It was determined that 
depletion of Teff by 5-FU is required to improve selection for Treg in culture, as with MTX. It was 
also found that 5-FU acted independently of TYMS to select Treg by increasing LAP expression 
and suppression of Teff proliferation. Both actions of 5-FU were similar to MTX but independent 
of thymidine synthesis. In the pathway diagram in Figure 22, we hypothesize that 5-FU 
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inhibition of ribosomal processing[85, 99] independently led to inhibition of eEF2, which is known 
to occur during ribosomal stress.[151] This hypothesis has not yet been tested, but would support 
our findings that MTX and 5-FU in combination enhance the selection of Treg independent of 
thymidine synthesis and that the addition of 5-FU improves Treg selection above MTX alone.   
A novel finding of our study was that aminoglycosides deplete Treg at high doses. This 
finding was supported by rescue of Treg from G418 mediated depletion when Neomycin 
resistance gene, which prevents G418 toxicity,[45] was present. Furthermore, multiple 
aminoglycosides were able to decrease the percent of TCD4, FoxP3, and studies in isolated Treg 
demonstrated that this treatment was specifically toxic to Treg. The mechanisms through which 
aminoglycosides mediate toxicity are diverse,[147] and were not addressed in these studies. We 
hypothesize that inhibition of mammalian translational elongation eEF2 was the factor 
determining aminoglycoside susceptibility. G418 and gentamicin have been shown to inhibit the 
human and mitochondrial ribosomes at the concentrations used, [152] and could logically 
combine with inhibition of translational elongation in Treg to mediate cell death.   While 
aminoglycosides have been in use for several decades the capacity of this drug to deplete Treg 
has not been described. The most likely explanation for this is that the drug is used at much 
lower doses in vivo than those used to deplete Treg in vitro, and is often discontinued for toxicity 
to multiple tissues.[147] Also, due to toxicity, aminoglycosides are often second-line antibiotic 
therapeutics limited to critically-ill patients with systemic infection[153] where gross immune 
dysregulation is confounded by the mechanisms known to perpetuate sepsis.[154] We are in the 
process of testing whether aminoglycosides effectively deplete Treg in vivo, and if this is the 
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case, then pretreatment with aminoglycosides may become an effective means of enhancing 
anti-tumor immunity. This finding needs to be further developed in vivo before any conclusions 
can be made.     
  In conclusion , this study develops a mechanistic understanding of how multiple 
chemotherapeutics select or deplete Treg through AMPK activation and decreased eEF2 
activity. Understanding how Treg are selected and depleted can inform drug design and drug 
combination choices in the clinic. Here, we develop a better understanding of MTX, a first-line 
anti-inflammatory drug, and demonstrate that selection of Treg may be improved by combination 
with low-dose 5-FU or occasional addition of leucovorin to rescue slowly replicating Tregs from 
inhibition of folate and thymidine synthesis. These findings open up new understandings in the 
methods to target and treat disease as well as possible mechanisms of dysregulation in 
autoimmune disease. 
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CHAPTER 5 Discussion and Future Directions 
SYNOPSIS 
 These studies were developed with the intention of improving T cell therapeutics. Each 
aim is intended to expand the repertoire of in vitro ASIS methods and enhance the selection of 
desired T cells. While the objective of each study was achieved, the studies are limited to in 
vitro work. No in vivo data has been included in these studies to suggest that any of the 
phenotypic findings extend beyond in vitro observations. This is a clear caveat of this system. 
However, working with human cells has benefits and limitations, and an example will help in 
understanding this statement; a limitation might be that the depletion of Treg by aminoglycosides 
is not reproducible in a murine model, yet aminoglycosides could still target Treg in human cells. 
In fact, human Treg are well known to differ from murine Treg by phenotypic markers.[113] As 
aminoglycosides are a full class of FDA approved drugs with well-known pharmacokinetics and 
side effects,[153] the depletion of Treg could more easily be tested in humans in small scale 
clinical trials. This brings into question the necessity of an animal model for studies originally 
designed for human cells, as animal models have different biological backgrounds.  
There is another limitation of animal models in that they do not recapitulate the natural 
cellular environment. Consider CARL+ K562 as one example; CARL+ K562 could be compared 
with standard AaPC (clone.4) to assess differences in outcomes for patients receiving CAR+ T 
cell therapy. An animal model designed to assess the in vivo functionality of CAR grown on 
differing AaPC would utilize immunocompromised mice with xenograft tumor and xenograft T 
cells. With a few exceptions, these models do not recapitulate many aspects of the human 
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body or an intact immune system.[26] In the standard NSG mouse model there are no 
endogenous B cells or T cells, and a dysregulation in macrophages, this would clearly alter the 
environment experienced by CAR+ T cells and the immune response induced by the reaction of 
these cells towards the tumor.[155] It is a reasonable argument that an animal model assessing 
the differences between AaPC would miss potential differences between the two AaPC that 
could lead to gross differences in tumor eradication and patient survival. Thus, it might be more 
prudent to test AaPC differences directly in humans. In a clinical trial, a product with equivalent 
CAR expression on T cells could be compared for differences induced by growth on differing T 
cells whether propagated on CARL+ K562 or clone.4 K562. A clinical trial, while more 
expensive and complicated, would yield much more relevant data than a mouse model.  
Therefore, certain changes to methodology, such as novel in vitro ASIS methods might be 
better assessed in humans rather than mice. 
 Notwithstanding, a murine model would still be quite useful in assessing whether certain 
experimental findings can be repeated in an in vivo model. As an example, DHFRFS selected 
with MTX and grown on clone.4 AaPC yielded an almost uniform increase in the CD4+ T cell 
population in multiple experiments, while DHFRFS selected by MTX and grown on CARL+ K562 
through CAR did not change the CD4+ T cell predominance. This finding was difficult to explain, 
even though it was consistent with the published findings of others.[82] Based on our 
subsequent studies with MTX, it is likely that MTX was inducing activation of AMPK in our 
DHFRFS+ CAR+ T cells as well as the DHFRFS+ CAR+ T cells published by Jonnalagadda et 
al.[82] The long-term effects of AMPK activation is uncertain for CAR+ T cells and could be 
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beneficial[156] or detrimental[157] based on available data. An animal model would be ideal for 
discriminating the true outcome of this alteration in signaling.   
Overall, the data presented here is limited to in vitro studies and some aspects of the 
work remain to be resolved with further in vitro and in vivo studies. However, we believe that 
the aims and objectives were sufficiently achieved within our system to discuss the implications 
of this work on future preclinical and clinical studies. We believe that the following primary 
findings are not unique to our system and have biological and clinical implications: 
1) Genetically-modified T cells can be selected and propagated independent of 
antigen-specificity based on the use of a CAR containing a conserved domain that is 
recognized and ligated by CARL+ AaPC. 
2) Genetically-modified T cells can be selected and propagated independent of 
antigen-specificity utilizing AThyR transgenes DHFRFS and TYMSSS individually or 
together. 
3) AThyR transgenes DHFRFS and TYMSSS confer special properties to T cells in the 
presence of MTX: 
a. Cis-transgene co-expressed with DHFRFS can be titrated or up-regulated by 
applying varying concentrations of MTX 
b. Co-expression of TYMSSS with DHFRFS blunts the findings noted in a. 
c. Co-expression of TYMSSS with DHFRFS confers improved resistance to MTX 
d. Application of MTX in DHFRFS expressing T cells appears to perturb 
signaling pathways.  
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i. This is likely achieved through the AMPK pathway, but this remains 
to be proven 
4) Consistent selection of AThyR transgene TYMSSS depends upon the depletion of 5-
FU resistant T cells. 
5) High-dose aminoglycosides selectively deplete Treg in culture 
i. This is likely mediated by eEF2 inhibition, but remains to be proven 
6) MTX and 5-FU enhance selection of Treg in culture 
a. Through selective depletion of Teff 
b. Through enhanced expression of LAP, associated with TGF-β 
These findings were briefly discussed above. Here the biological context will be discussed with 
clinical implications discussed in the following section.  
 The objective to establish novel, transgenic, in vitro ASIS methods for T cell 
therapeutics has been achieved. We believe these technical improvements will make T cell 
therapy a safer and more reliable treatment option. Transgenic modifications to T cell products 
have been attempting to improve safety and reliability for decades.[43, 158] Unfortunately, these 
advances have suffered from technical issues and the immunogenicity of the transgenes 
chosen.[41, 159] As an example: The earliest reports of gene modification in human cells used 
drug resistance to select for transformed cells,[160] and drug resistance was the first reported 
gene modification in human T cells.[161] Drug resistance in T cells, [161] including resistance to 
MTX in T cells, [46, 82] has been under-utilized due to technical limitations regarding the 
transgenes chosen. That being transgenes originating from bacteria and viruses are 
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immunogenic[41, 159] while the non-immunogenic transgene resistant to MTX is not useful in the 
context of most cancers where higher doses of MTX and MTX analogs with higher anti-
thymidylate activity make transgenic resistance to MTX obsolete in vivo.[86] The technological 
advance reported here include the use of transgenes to confer a broader spectrum of 
chemotherapeutic drug resistance to common anti-thymidylate drugs, and the capacity to utilize 
these transgenes to modify expression of cis expressed transgenes for in vivo use. Likewise, it 
is possible that these drug resistance transgenes can alter signaling pathways responsible for 
T cell selection and survival when combined with MTX. Thus, the findings here expand the 
number of transgenic options for in vitro ASIS while increasing the in vivo utility of choosing 
these transgenes. For this reason we suspect that these transgenes will be integrated into 
strategies to select and deplete T cell therapeutics in vitro and in vivo achieving the overall goal 
of improving safety and efficacy in T cell therapeutics. 
 As mentioned, MTX-dependent alterations in transgene expression and intracellular 
signaling could be useful to manipulate T cell phenotype in vitro or in vivo towards a desired 
outcome. In transgenic T cell studies, phenotypic alterations tend to modulate survival and 
growth or apoptosis and cell death. An example of selection for survival is the transgenic 
modification of T cells to over-express Bcl-2, an inhibitor of apoptosis, to prevent T cell 
death.[162] A study by a different group utilized a constitutively active form of AKT to enhance T 
cell activity and survival.[163] These modifications, however, were independent of drug induction. 
Drug-dependent modifications to T cell phenotype are best exemplified by suicide genes. 
Suicide genes such as herpes simplex virus – thymidine kinase (HSV-TK) [158] and inducible 
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caspase 9 (iC9) [36] which induce T cell death when drug is added. However, prior to the 
addition of drug, these genes are not believed to substantially alter the phenotype of the T 
cell.[35]  
The drug-inducible modification of T cell phenotypes has broadened as several groups 
begin to explore the chimerization of cytokine signaling. The signaling of cytokine IL-4, which 
signals towards a Th2 phenotype in T cells and away from a cytotoxic Th1 phenotype[5] was 
chimerically modified to provide a proliferative Th1 signal to T cells similar to that of IL-2 or IL-
15. Although this signal utilized an endogenously produced IL-4, the protein could be used ex 
vivo to expand T cells by selectively altering biochemical signaling pathways.[42] This concept 
was later used by another group to transduce the extracellular presence of IL-4 into the 
intracellular signal of IL-7 in genetically-modified T cells. Ultimately the modified T cells were 
used in vivo to enhance clearance of IL-4 secreting tumors in a xenogeneic mouse model.[164] 
The use of endogenous proteins, such as IL-4, limits the capacity to selectively activate 
biochemical pathways in transgene expressing T cells. That is because systemic administration 
of IL-4 to a patient, while not as toxic as IL-2, and more selective towards transgenic T cells 
than IL-7 or IL-15, still has off-target effects on other immune cells and the entire body.[165, 166] In 
another study, a non-endogenous protein was used to activate cytokine signaling. A common 
protein was chemically conjugated with multiple small molecules.  A scFv-specific to the small 
molecule was chimerized by the addition of the modified protein and led to intracellular 
signaling in murine B cells. In this way, a drug with little direct physiological effects was used to 
cross-link and initiate biochemical signaling within the transgenically modified cells.[167] The use 
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of chimeric proteins to alter cytokine signaling of endogenous human proteins will likely 
continue. A recent abstract presentations detailed the chimerization of a TGF-β receptor with 
TLR4 signaling endodomains to remove the physiologic suppression of TGF-β on T cells.[168] 
Thus, the use of drug-susceptible transgenes to augment T cell phenotypes rather than ablate 
transgenic T cells is in a nascent stage. Above are the few reported transgenes targeting 
biochemical pathways. Here we suggest a novel transgene to target a biochemical signaling 
pathways. Also, we propose a different biochemical pathway than the cytokine signaling 
pathways typically targeted.  
Here we propose a novel method to selectively activate AMPK in the presence of MTX. 
This developed from the observation that MTX, in combination with DHFRFS, resulted in 
different T cell phenotypes depending on the context (reference Ch. 3 Figure 12 & 17, Ch. 4 
Figure 19 & 21). In Chapter 4, it was outlined how AMPK contributed partly to Treg outgrowth, 
and that DHFRFS when combined with MTX appears to stimulate the AMPK pathway towards 
enhanced Treg outgrowth. This was noted in strong stimulatory conditions where polyclonal CD3 
crosslinking was combined with strong costimulatory signaling. In these experiments, MTX 
treatment of DHFRFS-expressing cells resulted in CD4+ T cells predominance compared to un-
transformed T cells (Ch. 3 Figure 12). This should be contrasted with experiments where CAR+ 
T cells received stimulation solely through the stimulatory and costimulatory domains of CAR 
(Ch. 3 Figure 17). In the DHFRFS+, CAR+ T cell experiment, there was no difference from un-
manipulated T cells in CD4+ predominance. This isolated experiment, while consistent on 
repetition, appears to conflict with DHFRFS+ T cell experiments not using CAR.  
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A resolution to this conflict may be understood by making note of initial experiments 
with DHFRFS not presented here. Initial constructs of DHFRFS were designed to co-express with 
CD19-specific CAR as DHFRFS-2A-CAR on T cells. Attempts to grow T cells expressing 
DHFRFS-2A-CAR on the strongly stimulatory AaPC clone.4 expressing CD19, CD86, and 
CD137L, resulted in multiple failed experiments where CAR+ T cells did not selectively 
propagate in the presence of MTX (data not shown). Consequently, the development of an 
AaPC with no costimulation, CARL+ K562, permitted the propagation of DHFRFS-2A-CAR and 
the construct was easily developed, tested, and reported.[169] Therefore, CD3 and costimulatory 
signaling clearly play a role in toxic drug mediated depletion of CD8+ T cells.  
These experiments reported above were not designed for direct comparison and do not 
explicitly comment on the capacity of AMPK to select for one phenotype over another in the 
context of costimulation. With that noted, there have been a number of studies on AMPK 
signaling in the context of T cell activation that will assist in understanding this phenomenon: 
AMPK is considered a negative regulator of T cell activity.[170]  T cell activation leads to a 
metabolic switch to glycolysis that is required to sustain the rapid proliferation and biosynthetic 
pathways of an inflammatory T cell.[171] AMPK mediates an antagonistic signal against 
glycolysis and towards lipolysis, inhibiting biosynthetic pathways, and inhibiting proliferation, at 
least in part through inhibition of mTOR.[136] T cells deficient in AMPK lead to excessive 
inflammation and poorer outcomes in an animal model of disease such as experimental 
autoimmune encephalomyelitis (EAE).[157] Activation of AMPK also decreases lymphocyte 
involvement and disease severity in an experimental asthma model.[172] Loss of AMPK in T 
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cells results in excessive activation of CD8+ T cells towards an inflammatory phenotype of 
increased IFN-γ secretion.[148] The un-opposed switch towards glycolysis in CD8+ T cells 
prevents CD8+ T cell memory development, and AMPK deficient T cells fail to survive after the 
initial response to antigen.[156] The excessive secretion of cytokines seen in AMPK deficient 
CD8+ T cells was not noted in AMPK deficient CD4+ T cells.[148] On the opposite end of the 
spectrum, activation of AMPK during the experimental asthma model did decrease CD4+ T cell 
numbers and promoted Treg outgrowth.[172]  
The above studies, all performed in mice, confer with our findings in human cells; AMPK 
activation in CD4+ predominant T cells activated by TCR and costimulation leads to increases 
in Tregs. As mentioned the AMPK activation leads to mTOR inhibition,[136] and T cell specific 
mTOR knockouts in mice resulted in increases in the Treg population [173] similar to that seen 
with enhanced AMPK activation via metformin.[172] This points to the hypothesis in CD8+ T cells 
that rescue from drug depletion by CAR-mediated expansion will permit AMPK inducible T cell 
memory formation in DHFRFS, CAR+ T cells. An important component of this hypothesis is that 
administration of MTX to DHFRFS+ T cells will lead to AMPK activation in CD8+ T cells. It has 
been shown that inhibition of mTOR in CD8+ T cells following activation results in improved T 
cell memory upon repeat presentation of antigen.[174] Thus, the use of CAR with DHFRFS could 
potentially be used to selectively activate CD8+ T cell memory in transgenic T cells with the 
addition of MTX. This would constitute an attractive and novel method of selectively activating 
biochemical pathways to promote a desired T cell phenotype.  
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In conclusion, our studies start by developing simple in vitro ASIS methods for 
transgenic T cells, but lead to new strategies for understanding and manipulating the 
expression of T cell phenotypes. There was no expectation that developing tools for T cell 
selection and propagation would lead to a better understanding of T cell biology and novel 
transgenic techniques. However, the development of new tools often precedes discovery. It 
was after the development of AThyRs that we serendipitously found a method to selectively 
grow Treg, and based on this finding we subsequently developed a novel method for the 
depletion of Treg. The above work advocates for critical analysis of well controlled science. Had 
a simple screening of CD4+ and CD8+ T cell subset predominance been neglected, a whole 
avenue of Treg biology would have been missed. While this work remains incompletely 
understood, proceeding with clinical and preclinical work is merited based on the findings. 
CLINICAL IMPLICATIONS 
 Few cell therapies and no cell-based gene therapies are currently approved by the 
FDA.[20] This fact does not preclude the use of some transgenic techniques reported here to be 
used in Phase I – III clinical trials. CARL+ AaPC could easily be integrated into open and 
ongoing clinical trials involving CAR+ T cells. However, few groups in the United States outside 
of MD Anderson utilize CAR-mediated ex vivo expansion. The use of CARL may be quite 
limited as it depends on the development of a novel CAR without a validated AaPC. Our group 
has published three different CARs, one of which is CD19-specific CAR currently in clinical 
trials with a validated clone.4 AaPC.[175] Another targeting fungal antigens has all of the 
preclinical data performed using the same clone.4 AaPC as CD19-specific CAR but loaded with 
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an activating antibody.[176] The third was grown on CARL+ K562,[95] but has no plans for clinical 
development. Consequently, there is uncertainty with respect to further development of CARL+ 
AaPC, and for that reason the development and validation of a clinical-grade AaPC expressing 
CARL has not yet begun. It is unlikely CARL will have any clinical impact without the 
development of a clinical-grade AaPC. 
 In regard to the AThyR transgenes DHFRFS and TYMSSS, a combination therapy of 
AThyR+ T cells with AThy therapies is, a priori, a straight-forward means to improve anti-tumor 
immunity. However, our in vitro studies demonstrated that CD8+ T cells, the primary effectors of 
tumor immunity,[177] are selectively inhibited from outgrowth during polyclonal stimulation. In 
vivo studies would be necessary to compare this approach to re-infusion of activated T cells 
following chemotherapy. Re-infusion of activated T cells following chemotherapy would be 
much easier to perform than the extensive manipulation necessary to generate AThyR+ T cells. 
Expressing AThyRs may be advantageous as discussed above for activating biochemical 
pathways of interest or ensuring the inclusion of a suicide gene in CAR+ T cells. CAR-mediated 
expansion techniques would also maintain the cytotoxic CD8+ T cell population. Consequently, 
AThyRs seem to be more reasonable for use in CAR+ T cells, but the proposed uses of 
AThyR+ CAR+ T cells need to be validated in vivo. 
 The findings of selective increase or decrease in the Treg population using FDA 
approved drugs have the most immediate potential for clinical impact. Aminoglycosides, such 
as gentamicin, could be used in clinical trials targeting easily localized chronic infections and 
cancers. While we suspect that long-term systemic administration of aminoglycosides will 
148 
 
selectively deplete Treg in preference to other T cells, we also believe that the properties that 
lead to selective depletion of Treg are found in other tissues, such as the kidneys and nervous 
system.[153] Based on this understanding, we seek to target diseases of a local nature, and we 
propose the following clinical trials: 1) intra-lesional injection of gentamicin or penicillin (a non-
aminoglycoside antibiotic) into treatment resistant verrucae (a human papilloma virus 
infection)[178] with punch and excisional biopsies for assessment of inflammatory response and 
Treg persistence. 2) Ultrasound guided intratumoral injection of gentamicin or penicillin in newly 
diagnosed breast cancers with post-resection pathological assessment of tumor mass 
reduction, inflammatory response in tumor and lymph nodes, and Treg persistence.  If the above 
studies are consistent with Treg depletion and reduction or loss of tumor, then the following is 
proposed: 3) A randomized control trial treating metastatic melanoma and squamous cell 
carcinoma with intra-tumoral injections of gentamicin or penicillin followed by checkpoint 
blockade therapy involving either anti-CTLA-4[179] or PD-1 blockade.[180] We believe that this 
series of clinical trials will inform clinicians on the utility of depleting Tregs in chronic infection and 
cancer. We also believe this approach will avoid excessive risk to critical organs such as brain, 
heart, or lung. 
 Finally, we found that MTX and 5-FU both increase Treg selection and improve LAP 
expression in ex vivo expanded Treg. The methods described here provide a protocol for 
improved ex vivo expansion of Treg. Further refinement of the drug duration and drug 
combinations is necessary to develop a highly enriched and suppressive Treg population that is 
of clinical-grade. The combination of MTX with 5-FU may enhance suppressor cell outgrowth 
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when folate synthesis is rescued. It was seen in our in vitro model, and recapitulating the 
finding in vivo could lead to a new drug combination for the treatment of inflammatory 
disorders. A rodent model of an inflammatory disorder commonly treated by MTX such as 
rheumatoid arthritis (RA)[104] could be tested in conjunction with low-dose 5-FU and folinic acid 
replacement. Folinic acid, also called leucovorin, is commonly used to rescue folate synthesis 
during the treatment of high dose MTX.[181] If the animal model is consistent, a clinical trial in 
RA could assess the additional benefit versus toxicity of MTX plus low-dose 5-FU with folinic 
acid rescue in comparison to MTX alone.  
FUTURE DIRECTIONS 
The potential of CARL+ K562 to expand CAR+ T cells independent of antigen served as 
a simple tool to decrease the time required to thoroughly test and validate new specificities of 
CAR. We also noted CARL provides a unique opportunity to understand the influence of CAR 
signaling differences from typical T cell activation by TCR and co-stimulation. To further 
develop CARL as a tool in dissecting the optimal configuration of CAR, improvements in the 
CAR specificity towards CARL may be necessary. In studies (not shown here) defining the 
specificity of CARL towards CAR, it was determined that the likely binding region of CARL on 
CAR is in the CH3 domain of the IgG4 Fc stalk expressed on CAR. This is advantageous as all 
immunoglobulin Fc receptors bind IgG in the CH2 domain.[182] Fc receptors on the AaPC, such 
as CD32 or CD64, can ligate and activate CAR+ T cells containing the native CH2-CH3 IgG4 
with intact Fc binding domain (not shown here). While ligation via the Fc receptor may seem a 
simpler method to activate and expand CAR in vitro, CAR binding Fc receptors could lead 
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researchers to frivolous experiments and wasted time trying to explain inconsistent cytotoxicity 
of CAR+ T cells which is due to Fc binding rather than antigen specificity. The potential to bind 
Fc receptors in vivo also remains an issue. This has been observed both in vitro and in vivo by 
Jonnalagadda et al., where unmodified CAR Fc led to deleterious Fc binding in vitro and 
removal by myeloid cells in vivo. A mutation to the Fc binding sites of CAR IgG4 domain or 
removal of the CH2 domain abrogated these deleterious findings and led to improved survival in 
a xenograft mouse model. [183] To avoid this issue, we tested CAR containing mutations to the 
Fc binding regions of IgG4, as was done by Jonnalagadda et al., and observed no changes in 
the activation and propagation of CAR+ T cells by CARL (not shown here). Thus, CAR with the 
appropriate Fc mutations, or quite possibly only containing the CH3 domain, will be able to 
expand on CARL+ AaPC free from deleterious binding. The ability to ligate any specificity of 
CAR on the surface of a T cell without the risk of off-target activation opens up the potential to 
refine CAR+ T cell specificity and phenotype. 
CARL+ AaPC could be used to define the optimal signaling and antigen specificity 
requirements of CAR+ T cells in comparison to equivalent activation by TCR and costimulation. 
Currently, the field is trying to determine the optimal antigenic targets, scFv specificities, and 
endodomain signaling strengths to develop a CAR+ T cell that strongly targets and kills tumor. 
At the same time, the development of a proficient memory subset of T cells is sought to 
respond to resurgence of tumor associated antigen.[25] A philosophical divide is developing over 
what CAR design will best meet these needs;[25] a CAR with antigen specificity and 
costimulatory signaling occurring in series, or multiple antigen specificities with costimulatory 
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signaling occurring in parallel (See Figure 26A). The CAR protein that has already been 
described uses in-series activation, where each signaling domain is attached in series to the 
next signaling domain. Second-generation CAR signaling is in-series and a single scFv 
mediates a combination of TCR signal via CD3ζ and a costimulatory signal. The choice of 
costimulation is also contentious, but tends to be either CD28 or CD137.[24] Costimulation is not 
limited to one or two costimulatory signals and some authors have included multiples of 
costimulatory endodomains.[72] In parallel signaling uses several different specificity scFvs each 
promoting a different stimulatory or costimulatory signal to activate T cells when all antigens 
are present (See Figure 26A). This in parallel system was best demonstrated by Kloss et al., 
who used one CAR targeting CD19 with stimulatory domains to provide suboptimal activation 
while a second CAR targeting PSMA was also expressed on the T cell to provide costimulation. 
Sufficient signal for fully activating CAR+ T cells was possible when both CD19 and PSMA were 
present on the same T cell, and activation was not possible if only one antigen was present on 
a target cell.[184]  This study was a proof of concept with in vivo demonstration of efficacy. The 
idea was not new, and had been attempted in various permutations in the preceding 3 years 
without in vivo testing.[185, 186] Developing in-parallel CAR+ T cells has proven to be a technical 
challenge difficult to repeat among the various interested groups. This is likely due to the 
challenge of testing various antigen-specific scFvs with various signal strength combinations. 
Using viral vectors and no selective propagation, this is a feat difficult to comparatively test. 
Viral transformation of T cells with multiple transgenes requires selection or multiple stages of 
genetic transformation to develop cells sufficient for testing. CARL+ K562 presents a simple 
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solution to this problem as activation of CARs by CARL will propagate even a small percentage 
of T cells expressing the right combination of CARs to a uniform population. That is because 
CARL will only activate and propagate CAR+ T cells deriving sufficient signal strength from 
CAR. Therefore, CAR+ T cell propagation on CARL+ K562 is an independent test of sufficient 
signal strength for CAR combinations. This approach is not currently possible using any other 
system, and allows for testing of even more difficult questions challenging the field. One of 
these questions is whether in-series or in-parallel CARs provide better signal strength for 
activation and propagation. Another question is how CAR intrinsically differs from endogenous 
signaling via TCR, costimulation, and cytokines. An experiment proposed in Figure 26B 
demonstrates how un-modified T cells stimulated through TCR, CD28, and IL-2 - signals 1 
through 3, could be compared to chimerized receptors providing signals 1 through 3. The 
objective of these experiments would be to quantify differences between in-series and in-
parallel CAR+ T cell activation by the use of image cytometry. This study as designed would 
also begin to answer questions of how CAR signaling differs from endogenous TCR signaling 
by quantifying differences in signal strength across the multiple signaling pathways. 
Furthermore, these findings will be correlated with high-resolution microscopy to elucidate how 
localization of various CARs contribute to differences in signaling strength from endogenous 
TCR. This would be the first reductionist approach towards understanding CAR design for 
activation and propagation of T cells.   
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Figure 26 Future studies targeting biochemical signaling in T cells. A schematically 
represents CARs which signal in-series (I & II) or in parallel (III & IV). CAR I represents 1st 
generation CAR, II represents 2nd generation CAR, III & IV represent in-parallel CARs, and V 
represents a chimeric cytokine receptor. B shows the comparative testing of these constructs 
to unmodified T cells during the canonical activation of T cells through TCR, CD28, and IL-2. C 
presents an experimental approach to enhancing T cell memory using DHFRFS in combination 
with MTX. 
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A separate proposed study would try to optimize another key physiologic parameter of T 
cells – establishing T cell memory. Here, we proposed that DHFRFS in combination with MTX 
will activate AMPK, subsequently inhibit mTOR, and promote memory T cell formation in a drug 
inducible manner. This hypothesis is untested in CAR+ T cells and must be further studied. 
Figure 26C depicts the proposed future studies designed to test enhanced memory formation 
in DHFRFS+, CAR+ T cells.  
We believe that the proposed studies utilize the tools developed here to address 
fundamental issues which remain in developing and translating T cell therapeutics. Hopefully, 
using these tools will effectively answer questions of how to establish and maintain T cells 
therapies for the eradication of disease in humans. 
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